Bernard Moss
#31,102
Most Influential Person Now
American virologist
Bernard Moss's AcademicInfluence.com Rankings
Bernard Mossbiology Degrees
Biology
#919
World Rank
#1605
Historical Rank
#492
USA Rank
Virology
#14
World Rank
#15
Historical Rank
#5
USA Rank
Download Badge
Biology
Bernard Moss's Degrees
- Bachelors Biology University of California, Berkeley
- PhD Virology Stanford University
Similar Degrees You Can Earn
Why Is Bernard Moss Influential?
(Suggest an Edit or Addition)According to Wikipedia, Bernard Moss is a virologist at the National Institute of Allergy and Infectious Diseases, part of the United States National Institutes of Health. He is the Chief of the NIAID Laboratory of Viral Diseases and of the NIAID Genetic Engineering Section. He is known for his work on poxviruses.
Bernard Moss's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. (1986) (2047)
- HIV-specific cytotoxic T lymphocytes in seropositive individuals (1987) (797)
- Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine (2001) (753)
- In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity (1988) (726)
- Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques (1985) (717)
- Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. (2002) (672)
- Vaccinia virus: a selectable eukaryotic cloning and expression vector. (1982) (632)
- General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes (1984) (624)
- Nonreplicating vaccinia vector efficiently expresses recombinant genes. (1992) (615)
- Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein (1986) (570)
- Methylated nucleotides block 5′ terminus of HeLa cell messenger RNA (1975) (553)
- Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. (1996) (545)
- Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. (1985) (524)
- gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand (1998) (505)
- The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis (1995) (500)
- New mammalian expression vectors (1990) (486)
- Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis. (1997) (464)
- A Role for Tumor Necrosis Factor Receptor-2 and Receptor-interacting Protein in Programmed Necrosis and Antiviral Responses* (2003) (448)
- Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype (1985) (442)
- Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. (2004) (421)
- Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. (1999) (421)
- Compact, synthetic, vaccinia virus early/late promoter for protein expression. (1997) (395)
- An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. (1988) (394)
- Vaccinia virus: a tool for research and vaccine development (1991) (392)
- Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes (1987) (392)
- Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen (1983) (384)
- Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox (2004) (380)
- Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. (1990) (378)
- Cap-independent translation of mRNA conferred by encephalomyocarditis virus 5' sequence improves the performance of the vaccinia virus/bacteriophage T7 hybrid expression system. (1989) (372)
- Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. (2001) (367)
- Structure of vaccinia virus late promoters. (1989) (365)
- Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein (1991) (356)
- Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. (1990) (347)
- Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins (1988) (344)
- Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. (1997) (341)
- Genome Sequence of a Human Tumorigenic Poxvirus: Prediction of Specific Host Response-Evasion Genes (1996) (334)
- Inhibition of the complement cascade by the major secretory protein of vaccinia virus. (1990) (319)
- Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara (1996) (317)
- Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors (1988) (316)
- Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys (2013) (312)
- A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. (1990) (308)
- Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. (1986) (308)
- Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein (1991) (307)
- Transient dominant selection of recombinant vaccinia viruses (1990) (304)
- Assembly of vaccinia virus: role of the intermediate compartment between the endoplasmic reticulum and the Golgi stacks (1993) (302)
- A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. (1994) (300)
- Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. (1983) (298)
- Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. (1998) (293)
- Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses (2003) (292)
- Genome-wide analysis of vaccinia virus protein-protein interactions. (2000) (286)
- Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. (1995) (279)
- Induction of AIDS Virus-Specific CTL Activity in Fresh, Unstimulated Peripheral Blood Lymphocytes from Rhesus Macaques Vaccinated with a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen1 (2000) (276)
- Incompletely base-paired flip-flop terminal loops link the two DNA strands of the vaccinia virus genome into one uninterrupted polynucleotide chain (1982) (276)
- Oligonucleotide sequence signaling transcriptional termination of vaccinia virus early genes. (1987) (273)
- Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes (1987) (272)
- Poxvirus entry and membrane fusion. (2006) (269)
- Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. (1983) (268)
- HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. (1988) (264)
- Construction of synthetic immunogen: use of new T-helper epitope on malaria circumsporozoite protein. (1987) (260)
- Live recombinant vaccinia virus protects chimpanzees against hepatitis B (1984) (254)
- Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. (2004) (251)
- Conserved TAAATG sequence at the transcriptional and translational initiation sites of vaccinia virus late genes deduced by structural and functional analysis of the HindIII H genome fragment (1986) (251)
- Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. (1989) (250)
- Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. (1992) (248)
- Colocalization of transcription and translation within cytoplasmic poxvirus factories coordinates viral expression and subjugates host functions. (2007) (247)
- Role of cell-associated enveloped vaccinia virus in cell-to-cell spread (1992) (244)
- The genome of molluscum contagiosum virus: analysis and comparison with other poxviruses. (1997) (241)
- Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities (1994) (238)
- Methylated nucleotides block 5'-terminus of vaccinia virus messenger RNA. (1975) (233)
- Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses (1991) (232)
- Expression of the HTLV-III envelope gene by a recombinant vaccinia virus (1986) (226)
- Purification of mRNA guanylyltransferase and mRNA (guanine-7-) methyltransferase from vaccinia virions. (1975) (225)
- Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein (1988) (223)
- Deletion of the vaccinia virus growth factor gene reduces virus virulence (1988) (220)
- Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. (1989) (220)
- Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle. (1985) (220)
- 5'-Terminal and internal methylated nucleotide sequences in HeLa cell mRNA. (1976) (220)
- Prevention of vaccinia virus infection in imiminodeficient mice by vector-directed IL-2 expression (1987) (217)
- Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. (1992) (217)
- Overcoming Immunity to a Viral Vaccine by DNA Priming before Vector Boosting (2003) (215)
- Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles. (1993) (213)
- Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells (1984) (212)
- The vaccinia virus K3L gene product potentiates translation by inhibiting double-stranded-RNA-activated protein kinase and phosphorylation of the alpha subunit of eukaryotic initiation factor 2 (1992) (205)
- Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice. (1985) (204)
- Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing (2010) (202)
- IL-18 binding and inhibition of interferon gamma induction by human poxvirus-encoded proteins. (1999) (201)
- Inhibition of HeLa Cell Protein Synthesis by the Vaccinia Virion (1968) (199)
- Rifampicin : a Specific Inhibitor of Vaccinia Virus Assembly (1969) (199)
- The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12. (1998) (199)
- In vitro mutagenesis of the promoter region for a vaccinia virus gene: evidence for tandem early and late regulatory signals (1985) (198)
- Reduction of Simian-Human Immunodeficiency Virus 89.6P Viremia in Rhesus Monkeys by Recombinant Modified Vaccinia Virus Ankara Vaccination (2001) (197)
- Selection of recombinant vaccinia viruses on the basis of plaque formation. (1995) (196)
- Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination (1993) (196)
- Human monkeypox and smallpox viruses: genomic comparison (2001) (192)
- Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. (2001) (192)
- Recombinant vaccinia virus K3L gene product prevents activation of double-stranded RNA-dependent, initiation factor 2 alpha-specific protein kinase. (1993) (192)
- Nucleotide sequences at the N6-methyladenosine sites of HeLa cell messenger ribonucleic acid. (1977) (192)
- Poxvirus DNA replication. (2013) (192)
- Vaccinia virus expression vectors. (1987) (191)
- Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. (1999) (188)
- Structure of vaccinia virus early promoters. (1989) (188)
- Cytoplasmic expression system based on constitutive synthesis of bacteriophage T7 RNA polymerase in mammalian cells. (1990) (188)
- Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope (1992) (187)
- Protective Immunity to Vaccinia Virus Induced by Vaccination with Multiple Recombinant Outer Membrane Proteins of Intracellular and Extracellular Virions (2004) (185)
- Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells (1990) (182)
- An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. (1990) (181)
- Regulation of vaccinia virus transcription. (1990) (181)
- Vaccinia Virus Intracellular Movement Is Associated with Microtubules and Independent of Actin Tails (2001) (180)
- Synthesis and cellular location of the ten influenza polypeptides individually expressed by recombinant vaccinia viruses. (1987) (180)
- Vaccinia Virus Entry into Cells via a Low-pH-Dependent Endosomal Pathway (2006) (178)
- Comparative Efficacy of Recombinant Modified Vaccinia Virus Ankara Expressing Simian Immunodeficiency Virus (SIV) Gag-Pol and/or Env in Macaques Challenged with Pathogenic SIV (2000) (178)
- Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. (1996) (177)
- Fusion of intra- and extracellular forms of vaccinia virus with the cell membrane (1990) (177)
- Complete pathway for protein disulfide bond formation encoded by poxviruses (2002) (175)
- Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. (1997) (175)
- A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies. (1995) (174)
- Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus (1990) (171)
- Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. (1997) (169)
- Smallpox vaccines: targets of protective immunity (2011) (168)
- Protein composition of the vaccinia virus mature virion. (2007) (168)
- Regulated expression of foreign genes in vaccinia virus under the control of bacteriophage T7 RNA polymerase and the Escherichia coli lac repressor (1992) (166)
- Formation of a vaccinia virus structural polypeptide from a higher molecular weight precursor: inhibition by rifampicin. (1970) (166)
- Critical Role for Env as well as Gag-Pol in Control of a Simian-Human Immunodeficiency Virus 89.6P Challenge by a DNA Prime/Recombinant Modified Vaccinia Virus Ankara Vaccine (2002) (166)
- Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. (2008) (165)
- Interruption by Rifampin of an Early Stage in Vaccinia Virus Morphogenesis: Accumulation of Membranes Which Are Precursors of Virus Envelopes (1970) (165)
- Cytotoxic T cells specific for the circumsporozoite protein of Plasmodium falciparum (1988) (165)
- Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. (2011) (162)
- Regulation of complement activity by vaccinia virus complement-control protein. (1992) (160)
- Poxvirus multiprotein entry-fusion complex. (2005) (160)
- Immunization with a Modified Vaccinia Virus Expressing Simian Immunodeficiency Virus (SIV) Gag-Pol Primes for an Anamnestic Gag-Specific Cytotoxic T-Lymphocyte Response and Is Associated with Reduction of Viremia after SIV Challenge (2000) (158)
- Role of DNA replication in vaccinia virus gene expression: A naked template is required for transcription of three late trans-activator genes (1990) (156)
- A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp160. (1989) (156)
- Poxvirus Cell Entry: How Many Proteins Does it Take? (2012) (155)
- The Envelope Protein Encoded by the A33R Gene Is Required for Formation of Actin-Containing Microvilli and Efficient Cell-to-Cell Spread of Vaccinia Virus (1998) (155)
- Nucleotide sequence of the vaccinia virus thymidine kinase gene and the nature of spontaneous frameshift mutations (1983) (153)
- Homology between DNA polymerases of poxviruses, herpesviruses, and adenoviruses: nucleotide sequence of the vaccinia virus DNA polymerase gene. (1986) (152)
- N6, O2′-dimethyladenosine a novel methylated ribonucleoside next to the 5′ terminal of animal cell and virus mRNAs (1975) (152)
- Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene (1996) (152)
- Visualization of Intracellular Movement of Vaccinia Virus Virions Containing a Green Fluorescent Protein-B5R Membrane Protein Chimera (2001) (151)
- Immunogenicity and Protective Efficacy of Oligomeric Human Immunodeficiency Virus Type 1 gp140 (2001) (150)
- A viral member of the ERV1/ALR protein family participates in a cytoplasmic pathway of disulfide bond formation. (2000) (150)
- Hydroxylapatite chromatography of protein-sodium dodecyl sulfate complexes. A new method for the separation of polypeptide subunits. (1972) (149)
- Dissociation of progeny vaccinia virus from the cell membrane is regulated by a viral envelope glycoprotein: effect of a point mutation in the lectin homology domain of the A34R gene (1993) (149)
- Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes. (1986) (147)
- Calreticulin Interacts with Newly Synthesized Human Immunodeficiency Virus Type 1 Envelope Glycoprotein, Suggesting a Chaperone Function Similar to That of Calnexin (*) (1996) (147)
- Mapping of the vaccinia virus thymidine kinase gene by marker rescue and by cell-free translation of selected mRNA. (1982) (143)
- Analysis of the Monkeypox Virus Genome (2002) (142)
- Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. (1996) (141)
- IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. (1996) (140)
- Stringent chemical and thermal regulation of recombinant gene expression by vaccinia virus vectors in mammalian cells. (1995) (140)
- Binding region for human immunodeficiency virus (HIV) and epitopes for HIV-blocking monoclonal antibodies of the CD4 molecule defined by site-directed mutagenesis. (1988) (140)
- Letter: Protein cleavage and poxvirus morphogenesis: tryptic peptide analysis of core precursors accumulated by blocking assembly with rifampicin. (1973) (139)
- Different Patterns of Immune Responses but Similar Control of a Simian-Human Immunodeficiency Virus 89.6P Mucosal Challenge by Modified Vaccinia Virus Ankara (MVA) and DNA/MVA Vaccines (2002) (139)
- T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant. (1986) (138)
- Vaccinia virus-infected cells release a novel polypeptide functionally related to transforming and epidermal growth factors. (1985) (138)
- Homology between RNA polymerases of poxviruses, prokaryotes, and eukaryotes: nucleotide sequence and transcriptional analysis of vaccinia virus genes encoding 147-kDa and 22-kDa subunits. (1986) (138)
- Immunology 101 at poxvirus U: immune evasion genes. (2001) (138)
- The ectodomain of HIV‐1 env subunit gp41 forms a soluble, alpha‐helical, rod‐like oligomer in the absence of gp120 and the N‐terminal fusion peptide. (1996) (136)
- Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination (1988) (134)
- Role for the vaccinia virus A36R outer envelope protein in the formation of virus-tipped actin-containing microvilli and cell-to-cell virus spread. (1998) (133)
- Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies. (1994) (132)
- Mapping the fine specificity of a cytolytic T cell response to HIV-1 nef protein. (1990) (131)
- Vaccinia virus A17L open reading frame encodes an essential component of nascent viral membranes that is required to initiate morphogenesis (1996) (130)
- The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. (2005) (130)
- Nuclear localization of a double-stranded RNA-binding protein encoded by the vaccinia virus E3L gene. (1993) (129)
- Sequential Protein Synthesis Following Vaccinia Virus Infection (1968) (129)
- Induction of a Mucosal Cytotoxic T-Lymphocyte Response by Intrarectal Immunization with a Replication-Deficient Recombinant Vaccinia Virus Expressing Human Immunodeficiency Virus 89.6 Envelope Protein (1998) (128)
- Structure and stability of mRNA synthesized by vaccinia virus-encoded bacteriophage T7 RNA polymerase in mammalian cells. Importance of the 5' untranslated leader. (1989) (127)
- New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins. (1990) (127)
- Tandem repeats within the inverted terminal repetition of vaccinia virus DNA (1980) (127)
- Broad spectrum chemokine antagonistic activity of a human poxvirus chemokine homolog. (1998) (126)
- Anti-influenza virus cytotoxic T lymphocytes recognize the three viral polymerases and a nonstructural protein: responsiveness to individual viral antigens is major histocompatibility complex controlled (1987) (126)
- Distinctive nucleotide sequences adjacent to multiple initiation and termination sites of an early vaccinia virus gene (1981) (125)
- Protective Immunity in Macaques Vaccinated with a Modified Vaccinia Virus Ankara-Based Measles Virus Vaccine in the Presence of Passively Acquired Antibodies (2000) (124)
- Group-specific, major histocompatibility complex class I-restricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1-infected individual. (1988) (124)
- Combinations of Polyclonal or Monoclonal Antibodies to Proteins of the Outer Membranes of the Two Infectious Forms of Vaccinia Virus Protect Mice against a Lethal Respiratory Challenge (2005) (124)
- Recognition of cloned vesicular stomatitis virus internal and external gene products by cytotoxic T lymphocytes (1986) (124)
- Product review. New mammalian expression vectors. (1990) (123)
- Assembly of vaccinia virus: effects of rifampin on the intracellular distribution of viral protein p65 (1994) (123)
- Transcription of vaccinia virus early genes by enzymes isolated from vaccinia virions terminates downstream of a regulatory sequence (1986) (122)
- Cell proliferative response to vaccinia virus is mediated by VGF. (1988) (121)
- Vaccinia virus encodes two proteins that are structurally related to members of the plasma serine protease inhibitor superfamily (1989) (121)
- Identification of a vaccinia virus gene encoding a type I DNA topoisomerase. (1987) (121)
- Analysis of a large cluster of nonessential genes deleted from a vaccinia virus terminal transposition mutant. (1988) (120)
- Antibody Profiling by Proteome Microarray Reveals the Immunogenicity of the Attenuated Smallpox Vaccine Modified Vaccinia Virus Ankara Is Comparable to That of Dryvax (2007) (120)
- Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer. (1998) (119)
- Immunity from smallpox vaccine persists for decades: a longitudinal study. (2008) (119)
- The A34R glycoprotein gene is required for induction of specialized actin-containing microvilli and efficient cell-to-cell transmission of vaccinia virus (1997) (119)
- Purification and characterization of a transcription termination factor from vaccinia virions. (1987) (118)
- Modification of the 5' end of mRNA. Association of RNA triphosphatase with the RNA guanylyltransferase-RNA (guanine-7-)methyltransferase complex from vaccinia virus. (1980) (117)
- CD8+ T lymphocytes of patients with AIDS maintain normal broad cytolytic function despite the loss of human immunodeficiency virus-specific cytotoxicity. (1990) (117)
- An immunodominant class I-restricted cytotoxic T lymphocyte determinant of human immunodeficiency virus type 1 induces CD4 class II-restricted help for itself (1990) (116)
- Mapping and insertional mutagenesis of a vaccinia virus gene encoding a 13,800-Da secreted protein. (1989) (116)
- Expression Profiling of the Intermediate and Late Stages of Poxvirus Replication (2011) (115)
- Complete Nucleotide Sequences of Two Adjacent Early Vaccinia Virus Genes Located Within the Inverted Terminal Repetition (1982) (115)
- Vaccinia virus D10 protein has mRNA decapping activity, providing a mechanism for control of host and viral gene expression (2007) (114)
- In vitro translation of immediate early, early, and late classes of RNA from vaccinia virus-infected cells. (1979) (114)
- Attenuated Poxvirus-Based Simian Immunodeficiency Virus (SIV) Vaccines Given in Infancy Partially Protect Infant and Juvenile Macaques Against Repeated Oral Challenge With Virulent SIV (2005) (112)
- Characterization of vaccinia virus DNA topoisomerase I expressed in Escherichia coli. (1988) (111)
- Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. (1997) (110)
- Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein (2005) (110)
- Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein (1997) (109)
- Characterization and temporal regulation of mRNAs encoded by vaccinia virus intermediate-stage genes (1993) (108)
- Oligomeric Structure of the Human Immunodeficiency Virus Type 1 Envelope Protein on the Virion Surface (2002) (108)
- Mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: cytotoxic T cells (1987) (108)
- Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells (2002) (107)
- A soluble recombinant polypeptide comprising the amino-terminal half of the extracellular region of the CD4 molecule contains an active binding site for human immunodeficiency virus. (1988) (106)
- Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. (2011) (105)
- Poly(A) polymerase and a dissociable polyadenylation stimulatory factor encoded by vaccinia virus (1991) (105)
- An HLA-C-restricted CD8+ cytotoxic T-lymphocyte clone recognizes a highly conserved epitope on human immunodeficiency virus type 1 gag (1991) (104)
- Limited immunological recognition of critical malaria vaccine candidate antigens. (1988) (103)
- Degradation of host microRNAs by poxvirus poly(A) polymerase reveals terminal RNA methylation as a protective antiviral mechanism. (2012) (103)
- Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein. (1986) (103)
- Cap-specific mRNA (nucleoside-O2'-)-methyltransferase and poly(A) polymerase stimulatory activities of vaccinia virus are mediated by a single protein. (1992) (103)
- Purification of a factor required for transcription of vaccinia virus early genes. (1988) (103)
- Characterization of a Second Vaccinia Virus mRNA-Decapping Enzyme Conserved in Poxviruses (2007) (103)
- Modification of the 5'-terminus of mRNA by soluble guanylyl and methyl transferases from vaccinia virus. (1975) (101)
- Comparative Analysis of the Magnitude, Quality, Phenotype, and Protective Capacity of Simian Immunodeficiency Virus Gag-Specific CD8+ T Cells following Human-, Simian-, and Chimpanzee-Derived Recombinant Adenoviral Vector Immunization (2013) (101)
- Purification and characterization of a DNA-dependent RNA polymerase from vaccinia virions. (1980) (101)
- Highly Effective Control of an AIDS Virus Challenge in Macaques by Using Vesicular Stomatitis Virus and Modified Vaccinia Virus Ankara Vaccine Vectors in a Single-Boost Protocol (2004) (100)
- Inhibition of the Ubiquitin-Proteasome System Prevents Vaccinia Virus DNA Replication and Expression of Intermediate and Late Genes (2009) (100)
- Vaccinia Virus Entry into Cells Is Dependent on a Virion Surface Protein Encoded by the A28L Gene (2004) (100)
- Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge. (2000) (99)
- Structural requirements for class I MHC molecule-mediated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immunodeficiency virus envelope protein (1989) (99)
- Vaccinia virus strain differences in cell attachment and entry. (2009) (98)
- Cytoplasmic transcription system encoded by vaccinia virus. (1991) (98)
- Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus (2008) (98)
- Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. (2002) (98)
- Vaccinia Virus A21 Virion Membrane Protein Is Required for Cell Entry and Fusion (2005) (97)
- Transcriptional and translational mapping and nucleotide sequence analysis of a vaccinia virus gene encoding the precursor of the major core polypeptide 4b (1985) (96)
- Visualization of an inverted terminal repetition in vaccinia virus DNA. (1978) (96)
- Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza (1996) (96)
- Poxviruses as expression vectors. (1997) (96)
- Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus and protection of mice against lethal herpes simplex virus 1 infection. (1987) (96)
- Regulation of expression and nucleotide sequence of a late vaccinia virus gene (1984) (95)
- External scaffold of spherical immature poxvirus particles is made of protein trimers, forming a honeycomb lattice (2005) (95)
- Immunization of Newborn Rhesus Macaques with Simian Immunodeficiency Virus (SIV) Vaccines Prolongs Survival after Oral Challenge with Virulent SIVmac251 (2003) (95)
- Vaccinia Virus H2 Protein Is an Essential Component of a Complex Involved in Virus Entry and Cell-Cell Fusion (2005) (95)
- Bacterial-type DNA holliday junction resolvases in eukaryotic viruses. (2000) (94)
- Surface expression of viral glycoproteins is polarized in epithelial cells infected with recombinant vaccinia viral vectors. (1986) (94)
- E. coli beta-glucuronidase (GUS) as a marker for recombinant vaccinia viruses. (1995) (94)
- Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. (2006) (93)
- Mutational analysis of the core, spacer, and initiator regions of vaccinia virus intermediate-class promoters (1992) (92)
- Elicitation of High-Frequency Cytotoxic T-Lymphocyte Responses against both Dominant and Subdominant Simian-Human Immunodeficiency Virus Epitopes by DNA Vaccination of Rhesus Monkeys (2001) (92)
- Vaccinia Virus Intermediate Stage Transcription Is Complemented by Ras-GTPase-activating Protein SH3 Domain-binding Protein (G3BP) and Cytoplasmic Activation/Proliferation-associated Protein (p137) Individually or as a Heterodimer* (2004) (92)
- Plasmodium knowlesi sporozoite antigen: expression by infectious recombinant vaccinia virus. (1984) (92)
- Entry of Vaccinia Virus and Cell-Cell Fusion Require a Highly Conserved Cysteine-Rich Membrane Protein Encoded by the A16L Gene (2006) (91)
- Hepatitis B virus large surface protein is not secreted but is immunogenic when selectively expressed by recombinant vaccinia virus (1986) (91)
- The Product of the Vaccinia Virus L5R Gene Is a Fourth Membrane Protein Encoded by All Poxviruses That Is Required for Cell Entry and Cell-Cell Fusion (2005) (91)
- Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis (2013) (91)
- Skin Mast Cells Protect Mice against Vaccinia Virus by Triggering Mast Cell Receptor S1PR2 and Releasing Antimicrobial Peptides (2012) (90)
- Sequence complexity and relative abundance of vaccinia virus mRNA's synthesized in vivo and in vitro (1978) (89)
- Epitope-Mapping Studies Define Two Major Neutralization Sites on the Vaccinia Virus Extracellular Enveloped Virus Glycoprotein B5R (2005) (89)
- Reproduction of Poxviruses (1974) (89)
- Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. (1996) (89)
- Early transcription factor subunits are encoded by vaccinia virus late genes. (1990) (89)
- Sequence analysis, expression, and deletion of a vaccinia virus gene encoding a homolog of profilin, a eukaryotic actin-binding protein (1991) (89)
- Characterization of Primary Isolate-Like Variants of Simian-Human Immunodeficiency Virus (1999) (89)
- RNA polymerase-associated transcription specificity factor encoded by vaccinia virus. (1992) (88)
- Cell-free translation of early and late mRNAs selected by hybridization to cloned DNA fragments derived from the left 14 million to 72 million daltons of the vaccinia virus genome. (1981) (88)
- DNA Packaging Mutant: Repression of the Vaccinia Virus A32 Gene Results in Noninfectious, DNA-Deficient, Spherical, Enveloped Particles (1998) (87)
- Discovery of antivirals against smallpox. (2004) (87)
- The vaccinia virus H5R gene encodes late gene transcription factor 4: purification, cloning, and overexpression (1996) (87)
- Vaccinia Virus A36R Membrane Protein Provides a Direct Link between Intracellular Enveloped Virions and the Microtubule Motor Kinesin (2004) (87)
- Vaccinia Virus Structural Polypeptide Derived from a High-Molecular-Weight Precursor: Formation and Integration into Virus Particles (1970) (86)
- Regulation of Vaccinia Virus Morphogenesis: Phosphorylation of the A14L and A17L Membrane Proteins and C-Terminal Truncation of the A17L Protein Are Dependent on the F10L Kinase (1999) (85)
- Folding, assembly, and intracellular trafficking of the human immunodeficiency virus type 1 envelope glycoprotein analyzed with monoclonal antibodies recognizing maturational intermediates (1996) (85)
- Role of the I7 Protein in Proteolytic Processing of Vaccinia Virus Membrane and Core Components (2004) (85)
- Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate (2010) (85)
- Immature viral envelope formation is interrupted at the same stage by lac operator-mediated repression of the vaccinia virus D13L gene and by the drug rifampicin. (1992) (85)
- Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus (2007) (85)
- Extension of the transcriptional and translational map of the left end of the vaccinia virus genome to 21 kilobase pairs (1981) (84)
- mRNA(nucleoside-2'-)-methyltransferase from vaccinia virus. Characteristics and substrate specificity. (1978) (84)
- Preparation of Cell Cultures and Vaccinia Virus Stocks (2015) (84)
- Appraising the apoptotic mimicry model and the role of phospholipids for poxvirus entry (2009) (83)
- Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T 7 RNA polymerase ( eukaryotic expression vector / genetic engineering / transcriptional signals / poxvirus ) (83)
- Apoptosis induced by a postbinding step of vaccinia virus entry into Chinese hamster ovary cells. (1998) (83)
- Characterization of the Vaccinia Virus H3L Envelope Protein: Topology and Posttranslational Membrane Insertion via the C-Terminal Hydrophobic Tail (2000) (83)
- Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. (1999) (83)
- A cellular factor is required for transcription of vaccinia viral intermediate-stage genes. (1994) (82)
- Induction of Plasmodium falciparum transmission-blocking antibodies by recombinant vaccinia virus. (1991) (81)
- Marker rescue of the host range restriction defects of modified vaccinia virus Ankara. (1998) (80)
- Vaccinia Virus F9 Virion Membrane Protein Is Required for Entry but Not Virus Assembly, in Contrast to the Related L1 Protein (2006) (80)
- Cytotoxic T lymphocytes from HIV-1 seropositive individuals recognize immunodominant epitopes in Gp160 and reverse transcriptase. (1992) (80)
- An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes. (1990) (79)
- Poxvirus decapping enzymes enhance virulence by preventing the accumulation of dsRNA and the induction of innate antiviral responses. (2015) (79)
- Intermolecular duplexes formed from polyadenylylated vaccinia virus RNA (1979) (79)
- Vaccinia virus growth factor stimulates tyrosine protein kinase activity of A431 cell epidermal growth factor receptors (1986) (79)
- Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. (2009) (79)
- Two Nucleic Acid-dependent Nucleoside Triphosphate Phosphohydrolases from Vaccinia Virus PURIFICATION AND CHARACTERIZATION (1974) (78)
- Vaccinia Virus L1 Protein Is Required for Cell Entry and Membrane Fusion (2008) (78)
- Vaccinia virus thymidine kinase and neighboring genes: mRNAs and polypeptides of wild-type virus and putative nonsense mutants (1983) (78)
- Recognition of cloned influenza virus hemagglutinin gene products by cytotoxic T lymphocytes (1986) (78)
- Eukaryotic transient expression system dependent on transcription factors and regulatory DNA sequences of vaccinia virus. (1985) (77)
- GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. (2007) (77)
- Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. (2014) (77)
- 5'-Terminal and internal methylated nucleosides in herpes simplex virus type 1 mRNA (1977) (77)
- Characterization of a polyriboadenylate polymerase from vaccinia virions. (1975) (76)
- Identification of rpo30, a vaccinia virus RNA polymerase gene with structural similarity to a eucaryotic transcription elongation factor (1990) (75)
- Protein Kinase and Specific Phosphate Acceptor Proteins Associated with Vaccinia Virus Cores (1972) (75)
- Mutational analysis of the assembly domain of the HIV-1 envelope glycoprotein. (1993) (75)
- Factor-dependent transcription termination by vaccinia virus RNA polymerase. Evidence that the cis-acting termination signal is in nascent RNA. (1988) (74)
- Introduction of foreign DNA into the vaccinia virus genome by in vitro ligation: recombination-independent selectable cloning vectors. (1992) (74)
- Repression of Vaccinia Virus Holliday Junction Resolvase Inhibits Processing of Viral DNA into Unit-Length Genomes (2001) (74)
- Mapping of the vaccinia virus DNA polymerase gene by marker rescue and cell-free translation of selected RNA (1984) (74)
- Orthopoxvirus IL-18 binding proteins: affinities and antagonist activities. (2001) (74)
- Influence of 5'-terminal cap structure on the initiation of translation of vaccinia virus mRNA. (1978) (74)
- Resolution of vaccinia virus DNA concatemer junctions requires late-gene expression (1989) (74)
- Characterization of a Vaccinia Virus Mutant with a Deletion of the D10R Gene Encoding a Putative Negative Regulator of Gene Expression (2006) (74)
- Expression of the vaccinia virus genome: Analysis and mapping of mRNAs encoded within the inverted terminal repetition (1980) (73)
- Two nucleic acid-dependent nucleoside triphosphate phosphohydrolases from vaccinia virus. Nucleotide substrate and polynucleotide cofactor specificities. (1974) (73)
- Vaccinia Virus Uracil DNA Glycosylase Has an Essential Role in DNA Synthesis That Is Independent of Its Glycosylase Activity: Catalytic Site Mutations Reduce Virulence but Not Virus Replication in Cultured Cells (2003) (73)
- Stable expression of the vaccinia virus K1L gene in rabbit cells complements the host range defect of a vaccinia virus mutant (1994) (72)
- Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors. (1990) (72)
- Elucidating and Minimizing the Loss by Recombinant Vaccinia Virus of Human Immunodeficiency Virus Gene Expression Resulting from Spontaneous Mutations and Positive Selection (2009) (72)
- Functional and structural interactions between measles virus hemagglutinin and CD46 (1995) (72)
- The Membrane Fusion Step of Vaccinia Virus Entry Is Cooperatively Mediated by Multiple Viral Proteins and Host Cell Components (2011) (72)
- Vaccinia Virus A28L Gene Encodes an Essential Protein Component of the Virion Membrane with Intramolecular Disulfide Bonds Formed by the Viral Cytoplasmic Redox Pathway (2004) (71)
- Preclinical Studies of Human Immunodeficiency Virus/AIDS Vaccines: Inverse Correlation between Avidity of Anti-Env Antibodies and Peak Postchallenge Viremia (2009) (71)
- Membrane fusion during poxvirus entry. (2016) (71)
- Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges (2007) (70)
- Sequence of methylated nucleotides at the 5'-terminus of adenovirus-specific RNA (1976) (70)
- The Vaccinia Virus A33R Protein Provides a Chaperone Function for Viral Membrane Localization and Tyrosine Phosphorylation of the A36R Protein (2001) (69)
- Poxvirus DNA primase (2007) (69)
- Characterization of human immunodeficiency virus gag/pol gene products expressed by recombinant vaccinia viruses. (1988) (68)
- Modification of RNA by mRNA guanylyltransferase and mRNA (guanine-7-)methyltransferase from vaccinia virions. (1975) (67)
- Selective transcription of vaccinia virus genes in template dependent soluble extracts of infected cells (1983) (67)
- Structure and replication of vaccinia virus telomeres. (1983) (67)
- Formation of the guanylylated and methylated 5'-terminus of vaccinia virus mRNA. (1976) (67)
- Vaccinia Virus G9 Protein Is an Essential Component of the Poxvirus Entry-Fusion Complex (2006) (67)
- HeLa cell RNA (2'-O-methyladenosine-N6-)-methyltransferase specific for the capped 5'-end of messenger RNA. (1978) (67)
- Identification of the vaccinia virus gene encoding an 18-kilodalton subunit of RNA polymerase and demonstration of a 5' poly(A) leader on its early transcript (1990) (67)
- Correspondence of the Functional Epitopes of Poxvirus and Human Interleukin-18-Binding Proteins (2001) (67)
- The Human Immunodeficiency Virus Type 1 gp120 V2 Domain Mediates gp41-Independent Intersubunit Contacts (2000) (66)
- Vaccinia virus gene D12L encodes the small subunit of the viral mRNA capping enzyme. (1989) (66)
- Vaccinia VirusExpression Vector: Coexpression of1-Galactosidase Provides Visual Screening ofRecombinant VirusPlaques (1985) (66)
- Transfer of the inducible lac repressor/operator system from Escherichia coli to a vaccinia virus expression vector. (1989) (66)
- Resistance of vaccinia virus to rifampicin conferred by a single nucleotide substitution near the predicted NH2 terminus of a gene encoding an Mr 62,000 polypeptide. (1987) (66)
- Vaccinia virus E10R protein is associated with the membranes of intracellular mature virions and has a role in morphogenesis. (2000) (66)
- Vaccinia virus morphogenesis is interrupted when expression of the gene encoding an 11-kilodalton phosphorylated protein is prevented by the Escherichia coli lac repressor (1991) (65)
- Cell-mediated immune response toward viral envelope and core antigens in gibbon apes (Hylobates lar) chronically infected with human immunodeficiency virus-1. (1988) (65)
- Resolution of linear minichromosomes with hairpin ends from circular plasmids containing vaccinia virus concatemer junctions (1986) (65)
- Post-transcriptional modifications of mRNA. Purification and characterization of cap I and cap II RNA (nucleoside-2'-)-methyltransferases from HeLa cells. (1981) (65)
- Genome-Wide Analysis of the 5′ and 3′ Ends of Vaccinia Virus Early mRNAs Delineates Regulatory Sequences of Annotated and Anomalous Transcripts (2011) (65)
- SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. (2012) (65)
- Identification of Wild-Derived Inbred Mouse Strains Highly Susceptible to Monkeypox Virus Infection for Use as Small Animal Models (2010) (64)
- Golgi Network Targeting and Plasma Membrane Internalization Signals in Vaccinia Virus B5R Envelope Protein (2000) (64)
- Large-scale production and purification of a vaccinia recombinant-derived HIV-1 gp160 and analysis of its immunogenicity. (1989) (64)
- Purification and identification of a vaccinia virus-encoded intermediate stage promoter-specific transcription factor that has homology to eukaryotic transcription factor SII (TFIIS) and an additional role as a viral RNA polymerase subunit. (1994) (64)
- Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques. (2004) (64)
- Association of Vaccinia Virus Fusion Regulatory Proteins with the Multicomponent Entry/Fusion Complex (2007) (63)
- mRNA(nucleoside-2'-)-methyltransferase from vaccinia virus. Purification and physical properties. (1978) (63)
- Vaccinia Virus Nonstructural Protein Encoded by the A11R Gene Is Required for Formation of the Virion Membrane (2005) (63)
- Development and Use of a Vaccinia Virus Neutralization Assay Based on Flow Cytometric Detection of Green Fluorescent Protein (2003) (63)
- Irreversible Effects of Cycloheximide During the Early Period of Vaccinia Virus Replication (1970) (63)
- The cytoplasmic and transmembrane domains of the vaccinia virus B5R protein target a chimeric human immunodeficiency virus type 1 glycoprotein to the outer envelope of nascent vaccinia virions (1997) (63)
- Glutaredoxin homolog encoded by vaccinia virus is a virion-associated enzyme with thioltransferase and dehydroascorbate reductase activities. (1992) (62)
- Methylation of newly synthesized viral messenger RNA by an enzyme in vaccinia virus. (1974) (62)
- Generation of Recombinant Vaccinia Viruses (2017) (61)
- Evaluation of recombinant vaccinia virus--measles vaccines in infant rhesus macaques with preexisting measles antibody. (2000) (61)
- Salmon Gill Poxvirus, the Deepest Representative of the Chordopoxvirinae (2015) (60)
- Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. (2009) (60)
- Anchoring a secreted plasmodium antigen on the surface of recombinant vaccinia virus-infected cells increases its immunogenicity (1986) (59)
- Sequence homologies of diverse length tandem repetitions near ends of vaccinia virus genome suggest unequal crossing over. (1982) (59)
- DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime. (2004) (59)
- Elicitation of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Mucosal Compartments of Rhesus Monkeys by Systemic Vaccination (2002) (59)
- RNA polymerase-associated protein Rap94 confers promoter specificity for initiating transcription of vaccinia virus early stage genes. (1994) (58)
- Vaccinia virus expresses a novel profilin with a higher affinity for polyphosphoinositides than actin. (1994) (58)
- Deletion of a 9,000-base-pair segment of the vaccinia virus genome that encodes nonessential polypeptides (1981) (58)
- Deciphering Poxvirus Gene Expression by RNA Sequencing and Ribosome Profiling (2015) (58)
- Inducer-dependent conditional-lethal mutant animal viruses. (1991) (58)
- mRNA guanylyltransferase and mRNA (guanine-7-)-methyltransferase from vaccinia virions. Donor and acceptor substrate specificites. (1976) (58)
- Role of Vaccinia Virus A20R Protein in DNA Replication: Construction and Characterization of Temperature-Sensitive Mutants (2001) (58)
- DNA-dependent ATPase activity associated with vaccinia virus early transcription factor. (1988) (57)
- Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene. (2005) (57)
- Targeting of a multicomponent transcription apparatus into assembling vaccinia virus particles requires RAP94, an RNA polymerase-associated protein (1994) (57)
- Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine. (2006) (56)
- Heterologously expressed serotonin 1A receptors couple to muscarinic K+ channels in heart. (1991) (56)
- Human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus env proteins possess a functionally conserved assembly domain (1990) (56)
- Comparison of the relative roles of the F and HN surface glycoproteins of the paramyxovirus simian virus 5 in inducing protective immunity (1987) (56)
- Capped poly(A) leaders of variable lengths at the 5' ends of vaccinia virus late mRNAs (1989) (56)
- Methylated 5'-terminal sequences of vaccinia virus mRNA species made in vivo at early and late times after infection. (1977) (56)
- Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization. (2008) (56)
- Vaccinia Virus G7L Protein Interacts with the A30L Protein and Is Required for Association of Viral Membranes with Dense Viroplasm To Form Immature Virions (2003) (56)
- Different H–2 subregions influence immunization against retrovirus and immunosuppression (1987) (56)
- Identification of Restriction Factors by Human Genome-Wide RNA Interference Screening of Viral Host Range Mutants Exemplified by Discovery of SAMD9 and WDR6 as Inhibitors of the Vaccinia Virus K1L−C7L− Mutant (2015) (56)
- CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses. (1989) (55)
- Vaccinia Virus G4L Glutaredoxin Is an Essential Intermediate of a Cytoplasmic Disulfide Bond Pathway Required for Virion Assembly (2002) (55)
- Sedimentation of an RNA polymerase complex from vaccinia virus that specifically initiates and terminates transcription. (1987) (55)
- Preparation of cell cultures and vaccinia virus stocks. (2001) (55)
- Accidental human vaccination with vaccinia virus expressing nucleoprotein gene (1986) (55)
- Hybridization selection and cell-free translation of mRNA's encoded within the inverted terminal repetition of the vaccinia virus genome (1981) (54)
- Reconsidering targeted toxins to eliminate HIV infection: you gotta have HAART. (1998) (54)
- DNA-dependent RNA polymerase subunits encoded within the vaccinia virus genome (1987) (54)
- Ancient Gene Capture and Recent Gene Loss Shape the Evolution of Orthopoxvirus-Host Interaction Genes (2021) (54)
- Evidence against an Essential Role of COPII-Mediated Cargo Transport to the Endoplasmic Reticulum-Golgi Intermediate Compartment in the Formation of the Primary Membrane of Vaccinia Virus (2003) (54)
- HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge (2019) (54)
- Identification of human and mouse homologs of the MC51L-53L-54L family of secreted glycoproteins encoded by the Molluscum contagiosum poxvirus. (1999) (53)
- The 1.51-Å structure of the poxvirus L1 protein, a target of potent neutralizing antibodies (2005) (53)
- Characterization of a Newly Identified 35-Amino-Acid Component of the Vaccinia Virus Entry/Fusion Complex Conserved in All Chordopoxviruses (2009) (53)
- Specific lysis of human immunodeficiency virus type 1-infected cells by a HLA-A3.1-restricted CD8+ cytotoxic T-lymphocyte clone that recognizes a conserved peptide sequence within the gp41 subunit of the envelope protein. (1991) (53)
- Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA. (2008) (53)
- Polyadenylate polymerase from vaccinia virions. (1973) (53)
- Effects of Deletion or Stringent Repression of the H3L Envelope Gene on Vaccinia Virus Replication (2000) (53)
- Transcription of vaccinia virus mRNA coupled to translation in vitro. (1978) (53)
- Transcription of vaccinia virus early genes by a template-dependent soluble extract of purified virions (1985) (53)
- Preparation of Cell Cultures and Vaccinia Virus Stocks (1998) (53)
- Vaccinia Virus F13L Protein with a Conserved Phospholipase Catalytic Motif Induces Colocalization of the B5R Envelope Glycoprotein in Post-Golgi Vesicles (2001) (52)
- Vaccinia virus directed RNA and protein synthesis in the presence of rifampicin. (1969) (52)
- Engineering of a vaccinia virus bacterial artificial chromosome in Escherichia coli by bacteriophage λ–based recombination (2005) (52)
- Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus. (1995) (52)
- Herpes simplex virus (HSV)-specific human T-cell clones recognize HSV glycoprotein D expressed by a recombinant vaccinia virus (1986) (52)
- Characterization of Chimpanzee/Human Monoclonal Antibodies to Vaccinia Virus A33 Glycoprotein and Its Variola Virus Homolog In Vitro and in a Vaccinia Virus Mouse Protection Model (2007) (52)
- Hepatitis B virus (HBV)-specific cytotoxic T-cell (CTL) response in humans: characterization of HLA class II-restricted CTLs that recognize endogenously synthesized HBV envelope antigens (1992) (52)
- Down Regulation of Gene Expression by the Vaccinia Virus D10 Protein (1999) (52)
- Instability and reiteration of DNA sequences within the vaccinia virus genome. (1981) (51)
- Reverse guanine phosphoribosyltransferase selection of recombinant vaccinia viruses. (1990) (51)
- Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate. (2007) (51)
- Pervasive Initiation and 3′-End Formation of Poxvirus Postreplicative RNAs* (2012) (50)
- Immune-defense molecules of molluscum contagiosum virus, a human poxvirus. (2000) (50)
- CD40L-Adjuvanted DNA/Modified Vaccinia Virus Ankara Simian Immunodeficiency Virus SIV239 Vaccine Enhances SIV-Specific Humoral and Cellular Immunity and Improves Protection against a Heterologous SIVE660 Mucosal Challenge (2014) (50)
- Anchor sequence-dependent endogenous processing of human immunodeficiency virus 1 envelope glycoprotein gp160 for CD4+ T cell recognition (1990) (50)
- Synergistic neutralizing activities of antibodies to outer membrane proteins of the two infectious forms of vaccinia virus in the presence of complement. (2004) (50)
- Codelivery of Envelope Protein in Alum with MVA Vaccine Induces CXCR3-Biased CXCR5+ and CXCR5− CD4 T Cell Responses in Rhesus Macaques (2015) (50)
- Poxvirus DNA topoisomerase knockout mutant exhibits decreased infectivity associated with reduced early transcription (2003) (50)
- Utilization of the guanylyltransferase and methyltransferases of vaccinia virus to modify and identify the 5'-terminals of heterologous RNA species. (1977) (50)
- Inhibition of host protein synthesis by vaccinia virus: fate of cell mRNA and synthesis of small poly (A)-rich polyribonucleotides in the presence of actinomycin D (1975) (50)
- Molecular cloning and sequence of the concatemer junction from vaccinia virus replicative DNA. Viral nuclease cleavage sites in cruciform structures. (1988) (49)
- Oligomeric structure of virion-associated and soluble forms of the simian immunodeficiency virus envelope protein in the prefusion activated conformation (2001) (49)
- Restriction of vaccinia virus replication in CHO cells occurs at the stage of viral intermediate protein synthesis. (1995) (49)
- HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges. (2006) (49)
- Complementation of a vaccinia virus host-range K1L gene deletion by the nonhomologous CP77 gene. (1996) (49)
- One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection (2021) (49)
- Assembly and Disassembly of the Capsid-Like External Scaffold of Immature Virions during Vaccinia Virus Morphogenesis (2009) (49)
- Processing, surface expression, and immunogenicity of carboxy-terminally truncated mutants of G protein of human respiratory syncytial virus (1989) (49)
- Stimulation of poly(A) tail elongation by the VP39 subunit of the vaccinia virus-encoded poly(A) polymerase. (1993) (48)
- The Vaccinia Virus A14.5L Gene Encodes a Hydrophobic 53-Amino-Acid Virion Membrane Protein That Enhances Virulence in Mice and Is Conserved among Vertebrate Poxviruses (2000) (48)
- Domain structure, intracellular trafficking, and beta2-microglobulin binding of a major histocompatibility complex class I homolog encoded by molluscum contagiosum virus. (1998) (48)
- Retrograde Transport from Early Endosomes to the trans-Golgi Network Enables Membrane Wrapping and Egress of Vaccinia Virus Virions (2016) (48)
- The glycoprotein products of varicella-zoster virus gene 14 and their defective accumulation in a vaccine strain (Oka) (1990) (48)
- Multiple 3' ends of mRNA encoding vaccinia virus growth factor occur within a series of repeated sequences downstream of T clusters (1986) (47)
- Identification of the vaccinia virus gene encoding nucleoside triphosphate phosphohydrolase I, a DNA-dependent ATPase (1987) (47)
- High-speed mass transit for poxviruses on microtubules (2001) (47)
- Vaccinia Virus A26 and A27 Proteins Form a Stable Complex Tethered to Mature Virions by Association with the A17 Transmembrane Protein (2008) (47)
- Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen. (1998) (47)
- Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines. (2008) (47)
- Modification of the 5' terminus of mRNA by an RNA (guanine-7-)-methyltransferase from HeLa cells. (1976) (47)
- Eukaryotic mRNA capping enzyme-guanylate covalent intermediate. (1982) (47)
- Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component. (2004) (47)
- Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques. (2003) (46)
- Existence of an operative pathway from the endoplasmic reticulum to the immature poxvirus membrane (2006) (46)
- A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. (1990) (46)
- Mutations in the Vaccinia Virus A33R and B5R Envelope Proteins That Enhance Release of Extracellular Virions and Eliminate Formation of Actin-Containing Microvilli without Preventing Tyrosine Phosphorylation of the A36R Protein (2003) (46)
- Two Distinct Low-pH Steps Promote Entry of Vaccinia Virus (2007) (46)
- Mapping and Functional Analysis of Interaction Sites within the Cytoplasmic Domains of the Vaccinia Virus A33R and A36R Envelope Proteins (2003) (46)
- Frame-shift mutations within the vaccinia virus A-type inclusion protein gene. (1992) (45)
- A complex of seven vaccinia virus proteins conserved in all chordopoxviruses is required for the association of membranes and viroplasm to form immature virions. (2004) (45)
- Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques. (2011) (45)
- Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen (1988) (45)
- Poxvirus membrane biogenesis. (2015) (45)
- Lethal Monkeypox Virus Infection of CAST/EiJ Mice Is Associated with a Deficient Gamma Interferon Response (2012) (45)
- Vaccinia Virus A56/K2 Fusion Regulatory Protein Interacts with the A16 and G9 Subunits of the Entry Fusion Complex (2008) (45)
- Heterologous Prime-Boost Regimens Using rAd35 and rMVA Vectors Elicit Stronger Cellular Immune Responses to HIV Proteins Than Homologous Regimens (2012) (45)
- Predicted poxvirus FEN1-like nuclease required for homologous recombination, double-strand break repair and full-size genome formation (2009) (45)
- Reflections on the early development of poxvirus vectors. (2013) (45)
- Mapping interaction sites of the A20R protein component of the vaccinia virus DNA replication complex. (2002) (45)
- HIV-1 protease cleaves actin during acute infection of human T-lymphocytes. (1992) (45)
- Characterization of a protein kinase and two phosphate acceptor proteins from vaccinia virions. (1975) (44)
- Similarities in the Induction of Post-Golgi Vesicles by the Vaccinia Virus F13L Protein and Phospholipase D (2002) (44)
- Inverted terminal repetition in vaccinia virus DNA encodes early mRNAs (1980) (44)
- Identification of a transcription factor, encoded by two vaccinia virus early genes, that regulates the intermediate stage of viral gene expression. (1999) (44)
- Envelope Formation Is Blocked by Mutation of a Sequence Related to the HKD Phospholipid Metabolism Motif in the Vaccinia Virus F13L Protein (1999) (44)
- Protection against lethal Japanese encephalitis virus infection of mice by immunization with the highly attenuated MVA strain of vaccinia virus expressing JEV prM and E genes. (1999) (43)
- Identification of Second-Site Mutations That Enhance Release and Spread of Vaccinia Virus (2002) (43)
- Identification, sequence, and expression of the gene encoding a Mr 35,000 subunit of the vaccinia virus DNA-dependent RNA polymerase. (1991) (43)
- Intracellular Trafficking of a Palmitoylated Membrane-Associated Protein Component of Enveloped Vaccinia Virus (2003) (43)
- A Glutaredoxin, Encoded by the G4L Gene of Vaccinia Virus, Is Essential for Virion Morphogenesis (2000) (43)
- Orthopoxvirus species and strain differences in cell entry (2012) (43)
- Nucleotide sequence required for resolution of the concatemer junction of vaccinia virus DNA (1989) (42)
- Opposing Roles of Double-Stranded RNA Effector Pathways and Viral Defense Proteins Revealed with CRISPR-Cas9 Knockout Cell Lines and Vaccinia Virus Mutants (2016) (42)
- Glycoprotein synthesis in cells infected with vaccinia virus. II. A glycoprotein component of the virion. (1971) (42)
- In vitro synthesis of vaccinia virus late mRNA containing a 5' poly(A) leader sequence. (1987) (42)
- Characterization of a 7-kilodalton subunit of vaccinia virus DNA-dependent RNA polymerase with structural similarities to the smallest subunit of eukaryotic RNA polymerase II (1992) (42)
- Priming with a Simplified Intradermal HIV-1 DNA Vaccine Regimen followed by Boosting with Recombinant HIV-1 MVA Vaccine Is Safe and Immunogenic: A Phase IIa Randomized Clinical Trial (2015) (42)
- Synthesis, oligomerization, and biological activity of the human immunodeficiency virus type 2 envelope glycoprotein expressed by a recombinant vaccinia virus. (1990) (42)
- Expression of polyomavirus virion proteins by a vaccinia virus vector: association of VP1 and VP2 with the nuclear framework (1987) (42)
- DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge (2007) (42)
- Insertional mutagenesis of the vaccinia virus gene encoding a type I DNA topoisomerase: evidence that the gene is essential for virus growth. (1989) (41)
- Selective synthesis and secretion of particles composed of the hepatitis B virus middle surface protein directed by a recombinant vaccinia virus: induction of antibodies to pre-S and S epitopes (1987) (41)
- Vaccinia Virus A30L Protein Is Required for Association of Viral Membranes with Dense Viroplasm To Form Immature Virions (2001) (41)
- The Vaccinia Virus A9L Gene Encodes a Membrane Protein Required for an Early Step in Virion Morphogenesis (2000) (41)
- Potent Functional Antibody Responses Elicited by HIV-I DNA Priming and Boosting with Heterologous HIV-1 Recombinant MVA in Healthy Tanzanian Adults (2015) (41)
- Molluscum Contagiosum Virus Interleukin-18 (IL-18) Binding Protein Is Secreted as a Full-Length Form That Binds Cell Surface Glycosaminoglycans through the C-Terminal Tail and a Furin-Cleaved Form with Only the IL-18 Binding Domain (2003) (40)
- Yaba-Like Disease Virus: an Alternative Replicating Poxvirus Vector for Cancer Gene Therapy (2001) (40)
- Promoting Trimerization of Soluble Human Immunodeficiency Virus Type 1 (HIV-1) Env through the Use of HIV-1/Simian Immunodeficiency Virus Chimeras (2004) (40)
- The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys. (1998) (40)
- Preexisting Vaccinia Virus Immunity Decreases SIV-Specific Cellular Immunity but Does Not Diminish Humoral Immunity and Efficacy of a DNA/MVA Vaccine (2010) (39)
- Transcription of viral late genes is dependent on expression of the viral intermediate gene G8R in cells infected with an inducible conditional-lethal mutant vaccinia virus (1992) (39)
- A transcription factor for expression of vaccinia virus late genes is encoded by an intermediate gene (1991) (39)
- Intravenous and isolated limb perfusion delivery of wild type and a tumor-selective replicating mutant vaccinia virus in nonhuman primates. (2005) (39)
- Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology. (2004) (39)
- Promoter DNA contacts made by the vaccinia virus early transcription factor. (1991) (39)
- The D10 Decapping Enzyme of Vaccinia Virus Contributes to Decay of Cellular and Viral mRNAs and to Virulence in Mice (2013) (39)
- Vaccinia Virus G1 Protein, a Predicted Metalloprotease, Is Essential for Morphogenesis of Infectious Virions but Not for Cleavage of Major Core Proteins (2004) (38)
- Preparation of Cell Cultures and Vaccinia Virus Stocks (1998) (38)
- Phosphoprotein Component of Vaccinia Virions (1973) (38)
- Expression of the A56 and K2 Proteins Is Sufficient To Inhibit Vaccinia Virus Entry and Cell Fusion (2008) (38)
- 5'-Terminal capping of RNA by guanylyltransferase from HeLa cell nuclei. (1977) (38)
- Antibody-dependent cellular cytotoxicity specific for the envelope antigens of human immunodeficiency virus. (1988) (38)
- Early promoter-binding factor from vaccinia virions. (1987) (38)
- Evidence for an Essential Catalytic Role of the F10 Protein Kinase in Vaccinia Virus Morphogenesis (2004) (37)
- Identification of factors specific for transcription of the late class of vaccinia virus genes (1989) (37)
- Multiple Roles for ATP in the Synthesis and Processing of mRNA by Vaccinia Virus: Specific Inhibitory Effects of Adenosine (β,γ-Imido) Triphosphate (1978) (37)
- Signature for Long-Term Vaccine-Mediated Control of a Simian and Human Immunodeficiency Virus 89.6P Challenge: Stable Low-Breadth and Low-Frequency T-Cell Response Capable of Coproducing Gamma Interferon and Interleukin-2 (2005) (37)
- Overview of the vaccinia virus expression system. (2001) (37)
- A recombinant vaccinia virus expressing herpes simplex virus type 1 glycoprotein B induces cytotoxic T lymphocytes in mice. (1988) (37)
- In vitro transcription of the inverted terminal repetition of the vaccinia virus genome: correspondence of initiation and cap sites (1981) (37)
- Origin-independent plasmid replication occurs in vaccinia virus cytoplasmic factories and requires all five known poxvirus replication factors (2005) (36)
- Vaccinia Virus Mutants with Alanine Substitutions in the Conserved G5R Gene Fail To Initiate Morphogenesis at the Nonpermissive Temperature (2004) (36)
- Identification, sequence, and expression of the gene encoding the second-largest subunit of the vaccinia virus DNA-dependent RNA polymerase. (1991) (36)
- Interaction and mutual stabilization of the two subunits of vaccinia virus mRNA capping enzyme coexpressed in Escherichia coli. (1990) (36)
- Participation of Vaccinia Virus L2 Protein in the Formation of Crescent Membranes and Immature Virions (2011) (36)
- Multimeric CD4 binding exhibited by human and simian immunodeficiency virus envelope protein dimers (1992) (36)
- Vaccinia virus serpin-1 deletion mutant exhibits a host range defect characterized by low levels of intermediate and late mRNAs. (1999) (36)
- Direct Formation of Vaccinia Virus Membranes from the Endoplasmic Reticulum in the Absence of the Newly Characterized L2-Interacting Protein A30.5 (2013) (36)
- Determination of the transcriptional regulatory region of a vaccinia virus late gene (1987) (36)
- Bromouridine triphosphate inhibits transcription termination and mRNA release by vaccinia virions. (1989) (36)
- Removal of the cleavage site of recombinant feline immunodeficiency virus envelope protein facilitates incorporation of the surface glycoprotein in immune-stimulating complexes. (1994) (35)
- Expression of the vaccinia virus A2.5L redox protein is required for virion morphogenesis. (2002) (35)
- A Novel Mode of Poxvirus Superinfection Exclusion That Prevents Fusion of the Lipid Bilayers of Viral and Cellular Membranes (2014) (35)
- Interaction of the Vaccinia Virus RNA Polymerase-Associated 94-Kilodalton Protein with the Early Transcription Factor (2009) (35)
- De novo synthesis of the early transcription factor 70-kilodalton subunit is required for morphogenesis of vaccinia virions (1996) (35)
- Use of a bacterial expression vector to identify the gene encoding a major core protein of vaccinia virus (1985) (33)
- The African swine fever virus g5R protein possesses mRNA decapping activity. (2009) (33)
- CD40L-Adjuvanted DNA/Modified Vaccinia Virus Ankara Simian Immunodeficiency Virus (SIV) Vaccine Enhances Protection against Neutralization-Resistant Mucosal SIV Infection (2015) (33)
- A conserved poxvirus NlpC/P60 superfamily protein contributes to vaccinia virus virulence in mice but not to replication in cell culture. (2008) (33)
- Mutational analysis of a multifunctional protein, with mRNA 5' cap-specific (nucleoside-2'-O-)-methyltransferase and 3'-adenylyltransferase stimulatory activities, encoded by vaccinia virus. (1994) (33)
- Determination of the promoter region of an early vaccinia virus gene encoding thymidine kinase. (1987) (33)
- Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies. (1999) (33)
- Vaccinia virus entry/fusion complex subunit A28 is a target of neutralizing and protective antibodies. (2008) (32)
- Comparative live bioluminescence imaging of monkeypox virus dissemination in a wild-derived inbred mouse (Mus musculus castaneus) and outbred African dormouse (Graphiurus kelleni) (2014) (32)
- Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV. (2010) (32)
- Cascade regulation of vaccinia virus gene expression is modulated by multistage promoters. (2013) (32)
- Genetic evidence for vaccinia virus-encoded DNA polymerase: isolation of phosphonoacetate-resistant enzyme from the cytoplasm of cells infected with mutant virus (1982) (32)
- Roles of Vaccinia Virus Ribonucleotide Reductase and Glutaredoxin in DNA Precursor Biosynthesis (*) (1995) (32)
- A Conserved Sequence within the H2 Subunit of the Vaccinia Virus Entry/Fusion Complex Is Important for Interaction with the A28 Subunit and Infectivity (2008) (31)
- Vaccinia Virus E2L Null Mutants Exhibit a Major Reduction in Extracellular Virion Formation and Virus Spread (2008) (31)
- Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2. (1990) (31)
- Chemokine homolog of molluscum contagiosum virus: sequence conservation and expression. (1998) (31)
- Histone mRNAs contain blocked and methylated 5′ terminal sequences but lack methylated nucleosides at internal positions (1977) (31)
- Immunogenicity in Macaques of the Clinical Product for a Clade B DNA/MVA HIV Vaccine: Elicitation of IFN-γ, IL-2, and TNF-α Coproducing CD4 and CD8 T Cells (2007) (31)
- Transition from rapid processive to slow nonprocessive polyadenylation by vaccinia virus poly(A) polymerase catalytic subunit is regulated by the net length of the poly(A) tail. (1992) (31)
- Identification and expression of rpo19, a vaccinia virus gene encoding a 19-kilodalton DNA-dependent RNA polymerase subunit (1992) (31)
- Generation of Recombinant Vaccinia Viruses (2015) (31)
- Physical and Functional Interactions between Vaccinia Virus F10 Protein Kinase and Virion Assembly Proteins A30 and G7 (2004) (30)
- Vaccinia Virus H7 Protein Contributes to the Formation of Crescent Membrane Precursors of Immature Virions (2009) (30)
- Overexpression, purification, and late transcription factor activity of the 17-kilodalton protein encoded by the vaccinia virus A1L gene (1993) (30)
- Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques (2016) (30)
- Cellular DNA ligase I is recruited to cytoplasmic vaccinia virus factories and masks the role of the vaccinia ligase in viral DNA replication. (2009) (30)
- Membrane topology of the vaccinia virus A17L envelope protein. (1999) (30)
- Donor and acceptor specificities of HeLa cell mRNA guanylyltransferase. (1980) (30)
- Characterization of recombinant vaccinia viruses and their products. (1998) (30)
- A role for the host coatomer and KDEL receptor in early vaccinia biogenesis (2009) (30)
- Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge. (2003) (30)
- Topology of epitope-tagged F13L protein, a major membrane component of extracellular vaccinia virions. (2003) (29)
- Live viral vaccines for respiratory and enteric tract diseases. (1988) (29)
- Gene Expression Using the Vaccinia Virus/ T7 RNA Polymerase Hybrid System (1998) (29)
- Sequence of DNA complementary to a small RNA segment of influenza virus A/NT/60/68. (1981) (29)
- Regulation of Viral Intermediate Gene Expression by the Vaccinia Virus B1 Protein Kinase (2001) (29)
- First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector (2018) (29)
- A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques (2017) (29)
- Control of a Mucosal Challenge and Prevention of AIDS in Rhesus Macaques by a Multiprotein DNA/MVA Vaccine (2001) (28)
- Disparity between Levels of In Vitro Neutralization of Vaccinia Virus by Antibody to the A27 Protein and Protection of Mice against Intranasal Challenge (2008) (28)
- Congregation of Orthopoxvirus Virions in Cytoplasmic A-Type Inclusions Is Mediated by Interactions of a Bridging Protein (A26p) with a Matrix Protein (ATIp) and a Virion Membrane-Associated Protein (A27p) (2010) (28)
- SP6 RNA polymerase containing vaccinia virus for rapid expression of cloned genes in tissue culture. (1993) (28)
- Why the smallpox virus stocks should not be destroyed. (1993) (28)
- Assembly of vaccinia virus particles from polypeptides made in the presence of rifampicin. (1971) (28)
- Recombinant vaccinia viruses as new live vaccines. (1984) (28)
- Amino acid substitutions at multiple sites within the vaccinia virus D13 scaffold protein confer resistance to rifampicin. (2007) (28)
- Analysis of Viral Membranes Formed in Cells Infected by a Vaccinia Virus L2-Deletion Mutant Suggests Their Origin from the Endoplasmic Reticulum (2012) (27)
- Drosophila S2 Cells Are Non-Permissive for Vaccinia Virus DNA Replication Following Entry via Low pH-Dependent Endocytosis and Early Transcription (2011) (27)
- A concept of eliminating nonhomologous recombination for scalable and safe AAV vector generation for human gene therapy (2013) (27)
- Interaction of the 82-kDa subunit of the vaccinia virus early transcription factor heterodimer with the promoter core sequence directs downstream DNA binding of the 70-kDa subunit. (1996) (27)
- Assembly of virus particles during mixed infection with wild-type vaccinia and a rifampicin-resistant mutant. (1971) (27)
- Repression of the A8L Gene, Encoding the Early Transcription Factor 82-Kilodalton Subunit, Inhibits Morphogenesis of Vaccinia Virions (1998) (27)
- Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge. (2009) (27)
- Duplication of the A17L Locus of Vaccinia Virus Provides an Alternate Route to Rifampin Resistance (2014) (27)
- Glycoprotein synthesis in cells infected with vaccinia virus. 3. Purification and biosynthesis of the virion glycoprotein. (1973) (27)
- Isolate- and group-specific immune responses to the envelope protein of human immunodeficiency virus induced by a live recombinant vaccinia virus in macaques. (1989) (27)
- Development and Use of a Vaccinia Virus Neutralization Assay Based on Flow Cytometric Detection of Green Fluorescent Protein (2003) (27)
- Abortive transcription products of vaccinia virus are guanylylated, methylated, and polyadenylylated (1979) (26)
- Anti-HIV activity of CD4-Pseudomonas exotoxin on infected primary human lymphocytes and monocyte/macrophages. (1991) (26)
- Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs. (2005) (26)
- Vaccinia virus vectors. (1992) (26)
- Inhibition of vaccinia virus late protein synthesis by isatin-beta-thiosemicarbazone: characterization and in vitro translation of viral mRNA. (1979) (26)
- The 1.51-Angstrom structure of the poxvirus L1 protein, a target of potent neutralizing antibodies. (2005) (26)
- Role of Receptor-Mediated Endocytosis in the Formation of Vaccinia Virus Extracellular Enveloped Particles (2005) (26)
- Uridylate‐containing RNA sequences determine specificity for binding and polyadenylation by the catalytic subunit of vaccinia virus poly(A) polymerase. (1993) (26)
- Purification and characterization of mRNA guanylyltransferase from HeLa cell nuclei. (1980) (26)
- Herpes simplex virus type 1-vaccinia virus recombinant expressing glycoprotein B: protection from acute and latent infection. (1988) (25)
- A New Multi-clade DNA Prime/Recombinant MVA Boost Vaccine Induces Broad and High Levels of HIV-1-specific CD8+ T-cell and Humoral Responses in Mice. (2007) (25)
- Topology of Endoplasmic Reticulum‐Associated Cellular and Viral Proteins Determined with Split‐GFP (2015) (25)
- Generation of Recombinant Vaccinia Viruses (1998) (25)
- Reverse Genetics Analysis of Poxvirus Intermediate Transcription Factors (2012) (25)
- A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice. (2007) (25)
- Identification of Poxvirus Genome Uncoating and DNA Replication Factors with Mutually Redundant Roles (2018) (25)
- Transport to the cell surface of a peptide sequence attached to the truncated C terminus of an N-terminally anchored integral membrane protein (1988) (25)
- Viruses know more than one way to don a cap (2010) (25)
- Vaccinia virus-mediated expression and identification of the human poliovirus receptor. (1991) (25)
- Susceptibility of the wild-derived inbred CAST/Ei mouse to infection by orthopoxviruses analyzed by live bioluminescence imaging (2013) (25)
- Roles of vaccinia virus in the development of new vaccines. (1988) (25)
- Transcriptional and translational mapping of a 6.6-kilobase-pair DNA fragment containing the junction of the terminal repetition and unique sequence at the left end of the vaccinia virus genome (1981) (24)
- Disulfide Bonds and Membrane Topology of the Vaccinia Virus A17L Envelope Protein (2000) (24)
- Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously immunized animals (2005) (24)
- Glycoprotein synthesis in cells infected with vaccinia virus. I. Non-virion glycoproteins. (1971) (24)
- Lipid Membranes in Poxvirus Replication (2010) (24)
- High level protein expression in mammalian cells using a safe viral vector: modified vaccinia virus Ankara. (2007) (23)
- Studies using a recombinant vaccinia virus expressing the circumsporozoite protein of Plasmodium berghei. (1991) (23)
- Reversal of Anti-viral Effects of Rifampicin (1970) (23)
- Poxvirus vectors: cytoplasmic expression of transferred genes. (1993) (23)
- Prior Vaccination Increases the Epitopic Breadth of the Cytotoxic T-Lymphocyte Response That Evolves in Rhesus Monkeys following a Simian-Human Immunodeficiency Virus Infection (2002) (23)
- Use of vaccinia virus vectors to study the synthesis, intracellular localization, and action of the human immunodeficiency virus trans-activator protein. (1988) (22)
- Sequence-Independent Targeting of Transmembrane Proteins Synthesized within Vaccinia Virus Factories to Nascent Viral Membranes (2007) (22)
- pUV I: a new vaccinia virus insertion and expression vector. (1987) (22)
- Vaccinia Virus C9 Ankyrin Repeat/F-Box Protein Is a Newly Identified Antagonist of the Type I Interferon-Induced Antiviral State (2018) (22)
- Transcription initiation factor activity of vaccinia virus capping enzyme is independent of mRNA guanylylation. (1993) (22)
- HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine (2017) (22)
- Modification of the cascade model for regulation of vaccinia virus gene expression: purification of a prereplicative, late-stage-specific transcription factor (1994) (22)
- Purification and use of vaccinia virus messenger RNA capping enzyme. (1990) (22)
- Ordered assembly of a functional preinitiation transcription complex, containing vaccinia virus early transcription factor and RNA polymerase, on an immobilized template (1994) (22)
- Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost (2017) (22)
- Sequence independent replication and sequence specific resolution of plasmids containing the vaccinia virus concatemer junction requirements for early and late trans acting factors (1988) (22)
- Zinc-finger antiviral protein (ZAP) is a restriction factor for replication of modified vaccinia virus Ankara (MVA) in human cells (2020) (22)
- Enigmatic origin of the poxvirus membrane from the endoplasmic reticulum shown by 3D imaging of vaccinia virus assembly mutants (2017) (21)
- Purification of a protein kinase and two phosphate acceptor proteins from vaccinia virions. (1975) (21)
- Recombinant CD4-Pseudomonas exotoxin hybrid protein displays HIV-specific cytotoxicity without affecting MHC class II-dependent functions. (1990) (21)
- Similar Effect of Rifampin and Other Rifamycin Derivatives on Vaccinia Virus Morphogenesis (1971) (21)
- Interaction between the G3 and L5 proteins of the vaccinia virus entry-fusion complex. (2011) (21)
- Primary HIV-1 isolates refractory to neutralization by soluble CD4 are potently inhibited by CD4-Pseudomonas exotoxin. (1993) (21)
- Vaccinia Virus L2 Protein Associates with the Endoplasmic Reticulum near the Growing Edge of Crescent Precursors of Immature Virions and Stabilizes a Subset of Viral Membrane Proteins (2011) (21)
- Mapping vaccinia virus DNA replication origins at nucleotide level by deep sequencing (2015) (21)
- Immunogenicity of recombinant vaccinia viruses that display the HIV type 1 envelope glycoprotein on the surface of infectious virions. (1997) (20)
- Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells. (2007) (20)
- Triad of human cellular proteins, IRF2, FAM111A, and RFC3, restrict replication of orthopoxvirus SPI-1 host-range mutants (2017) (20)
- Dose-response studies for the elicitation of CD8 T cells by a DNA vaccine, used alone or as the prime for a modified vaccinia Ankara boost. (2007) (20)
- Induction of Plasmodium falciparum transmission-blocking antibodies by recombinant Pfs25. (1992) (20)
- Single-stranded deoxyribonucleic acid-specific nuclease from vaccinia virus. Purification and characterization. (1974) (20)
- Vaccinia virus poly(A) polymerase. Specificity for nucleotides and nucleotide analogs. (1988) (20)
- Synthesis of mRNA guanylyltransferase and mRNA methyltransferases in cells infected with vaccinia virus (1977) (20)
- Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers. (2016) (19)
- Characterization of conformation-dependent anti-gp120 murine monoclonal antibodies produced by immunization with monomeric and oligomeric human immunodeficiency virus type 1 envelope proteins. (1999) (19)
- Vaccinia virus recombinants expressing rabiesvirus glycoprotein protect against rabies (1987) (19)
- Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants. (2013) (19)
- Vaccinia virus expression vector: a new tool for immunologists. (1985) (19)
- Purification and characterization of a HeLa cell transfer RNA(cytosine-5-)-methyltransferase. (1980) (19)
- Regulation of orthopoxvirus gene expression. (1990) (19)
- Poxvirus expression vectors. (1992) (19)
- Use of vaccinia virus as an infectious molecular cloning and expression vector. (1983) (19)
- Expression of ion channels and receptors in Xenopus oocytes using vaccinia virus (1991) (19)
- Regulation of Synthesis of Two Immunologically Distinct Nucleic Acid-Dependent Nucleoside Triphosphate Phosphohydrolases in Vaccinia Virus-Infected HeLa Cells (1974) (18)
- Protein Kinase Activity from Vaccinia Virions: Solubilization and Separation into Heat-Labile and Heat-Stable Components (1973) (18)
- Vaccinia virus: a selectable eukaryotic cloning and expression vector. 1982. (1992) (18)
- SPI-1 is a missing host-range factor required for replication of the attenuated modified vaccinia Ankara (MVA) vaccine vector in human cells (2019) (18)
- Cell-specific posttranslational events affect functional expression at the plasma membrane but not tetrodotoxin sensitivity of the rat brain IIA sodium channel alpha-subunit expressed in mammalian cells (1992) (18)
- A novel approach for the production of monoclonal antibodies using infectious vaccinia virus recombinants. (1987) (18)
- Effects of vaccinia virus uracil DNA glycosylase catalytic site and deoxyuridine triphosphatase deletion mutations individually and together on replication in active and quiescent cells and pathogenesis in mice (2008) (18)
- Genome Sequence of Erythromelalgia-Related Poxvirus Identifies it as an Ectromelia Virus Strain (2012) (18)
- Common Sequence at the 5′ Ends of the Segmented RNA Genomes of Influenza A and B Viruses (1978) (18)
- Preparation of Cell Cultures and Vaccinia Virus Stocks. (2017) (17)
- Elimination of A-type inclusion formation enhances cowpox virus replication in mice: Implications for orthopoxvirus evolution (2014) (17)
- Droplet digital PCR for rapid enumeration of viral genomes and particles from cells and animals infected with orthopoxviruses. (2017) (17)
- Single-stranded deoxyribonucleic acid-specific nuclease from vaccinia virus. Endonucleolytic and exonucleolytic activities. (1974) (17)
- Mutational analysis of a predicted zinc-binding motif in the 26-kilodalton protein encoded by the vaccinia virus A2L gene: correlation of zinc binding with late transcriptional transactivation activity (1993) (17)
- Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection (2022) (17)
- Clearance of recombinant vaccinia virus expressing IL-2: role of local host immune responses. (1993) (17)
- Virus entry--an unwilling collaboration by the cell. (2013) (17)
- Repair of a previously uncharacterized second host-range gene contributes to full replication of modified vaccinia virus Ankara (MVA) in human cells (2020) (17)
- The assembly of the HIV-1 env glycoprotein into dimers and tetramers. (1991) (17)
- A New Vaccinia Virus Intermediate Transcription Factor (1998) (17)
- Association of the Vaccinia Virus A11 Protein with the Endoplasmic Reticulum and Crescent Precursors of Immature Virions (2013) (17)
- Efficient priming of simian/human immunodeficiency virus (SHIV)-specific T-cell responses with DNA encoding hybrid SHIV/hepatitis B surface antigen particles. (2004) (17)
- Human Host Range Restriction of the Vaccinia Virus C7/K1 Double Deletion Mutant Is Mediated by an Atypical Mode of Translation Inhibition (2018) (16)
- Vaccinia virus-mediated inhibition of host protein synthesis involves neither degradation nor underphosphorylation of components of the cap-binding eukaryotic translation initiation factor complex eIF-4F. (1992) (16)
- Vaccinia Virus Encodes I5, a Small Hydrophobic Virion Membrane Protein That Enhances Replication and Virulence in Mice (2008) (16)
- Vaccinia and other poxvirus expression vectors. (1992) (16)
- Vaccinia virus: an expression vector for genes from parasites (1986) (16)
- Quaternary Structure and Cleavage Specificity of a Poxvirus Holliday Junction Resolvase* (2006) (16)
- Unique Temperature-Sensitive Defect in Vaccinia Virus Morphogenesis Maps to a Single Nucleotide Substitution in the A30L Gene (2001) (16)
- Strong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine (2016) (16)
- Activity of CD4-Pseudomonas exotoxin against cells expressing diverse forms of the HIV and SIV envelope glycoproteins. (1992) (16)
- Products and substrate/template usage of vaccinia virus DNA primase. (2009) (15)
- Recombinant Protein Synthesis in Chinese Hamster Ovary Cells Using a Vaccinia Virus/Bacteriophage T7 Hybrid Expression System* (1996) (15)
- Replicating and host-restricted non-replicating vaccinia virus vectors for vaccine development. (1994) (15)
- Transcriptional Repression and RNA Silencing Act Synergistically To Demonstrate the Function of the Eleventh Component of the Vaccinia Virus Entry-Fusion Complex (2011) (15)
- Identification of Vaccinia Virus Replisome and Transcriptome Proteins by Isolation of Proteins on Nascent DNA Coupled with Mass Spectrometry (2017) (15)
- The Molecular Biology of Poxviruses (1987) (15)
- Vaccinia virus F16 protein, a predicted catalytically inactive member of the prokaryotic serine recombinase superfamily, is targeted to nucleoli (2011) (15)
- Resistance of a vaccinia virus A34R deletion mutant to spontaneous rupture of the outer membrane of progeny virions on the surface of infected cells. (2007) (15)
- Natural killer cells expanded in vivo or ex vivo with IL-15 overcomes the inherent susceptibility of CAST mice to lethal infection with orthopoxviruses (2020) (15)
- Deoxyribonucleic Acid-Dependent Nucleotide Phosphohydrolase Activity in Purified Vaccinia Virus (1972) (15)
- Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge. (2012) (15)
- Use of vaccinia virus vectors for development of AIDS vaccines. (1988) (14)
- Inactivation of Genes by Frameshift Mutations Provides Rapid Adaptation of an Attenuated Vaccinia Virus (2020) (14)
- The destruction of smallpox virus stocks in national repositories: a grave mistake and a bad precedent. (1994) (14)
- Transcriptional mapping of the vaccinia virus DNA polymerase gene (1985) (14)
- Vaccinia Virus Polyriboadenylate Polymerase: Covalent Linkage of the Product with Polyribonucleotide and Polydeoxyribonucleotide Primers (1974) (14)
- Translation of specific vaccinia virus RNAs purified as RNA-DNA hybrids on potassium iodide gradients. (1979) (14)
- Sequence-Divergent Chordopoxvirus Homologs of the O3 Protein Maintain Functional Interactions with Components of the Vaccinia Virus Entry-Fusion Complex (2011) (14)
- Insufficient Innate Immunity Contributes to the Susceptibility of the Castaneous Mouse to Orthopoxvirus Infection (2017) (14)
- The Conserved Poxvirus L3 Virion Protein Is Required for Transcription of Vaccinia Virus Early Genes (2005) (14)
- Overview of the Vaccinia Virus Expression System (2002) (14)
- Transcription of a vaccinia virus late promoter template: requirement for the product of the A2L intermediate-stage gene (1996) (14)
- High Doses of GM-CSF Inhibit Antibody Responses in Rectal Secretions and Diminish Modified Vaccinia Ankara/Simian Immunodeficiency Virus Vaccine Protection in TRIM5α-Restrictive Macaques (2016) (14)
- 5' end labeling of RNA with capping and methylating enzymes. (1981) (14)
- Formation of Orthopoxvirus Cytoplasmic A-Type Inclusion Bodies and Embedding of Virions Are Dynamic Processes Requiring Microtubules (2012) (13)
- Modification of the 5'-terminals of mRNAs by viral and cellular enzymes. (1976) (13)
- T cell responses to respiratory syncytial virus fusion and attachment proteins in human peripheral blood mononuclear cells. (2006) (13)
- The 2.1 Å structure of protein F9 and its comparison to L1, two components of the conserved poxvirus entry-fusion complex (2018) (12)
- Genetic studies of the susceptibility of classical and wild-derived inbred mouse strains to monkeypox virus (2015) (12)
- Effects of a Temperature Sensitivity Mutation in the J1R Protein Component of a Complex Required for Vaccinia Virus Assembly (2005) (12)
- Interactions of the Vaccinia Virus A19 Protein (2013) (12)
- Post-transcriptional Modifications of mRNA (1981) (12)
- Identification of the viral molecules recognised by influenza specific human cytoxic T lymphocytes. (1987) (12)
- Purification and characterization of the messenger ribonucleic acid capping enzyme GTP:RNA guanylyltransferase from wheat germ. (1982) (12)
- Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization (2009) (12)
- Addition of the MSA1 signal and anchor sequences to the malaria merozoite surface antigen 1 C-terminal region enhances immunogenicity when expressed by recombinant vaccinia virus. (1997) (12)
- Novel Nonreplicating Vaccinia Virus Vector Enhances Expression of Heterologous Genes and Suppresses Synthesis of Endogenous Viral Proteins (2017) (12)
- Live vaccinia virus recombinants expressing herpes simplex virus genes. (1991) (12)
- Poxviruses Encode a Reticulon-Like Protein that Promotes Membrane Curvature. (2016) (11)
- Vaccinia Virus Expression Vectors a (1989) (11)
- Vaccinia Virus A19 Protein Participates in the Transformation of Spherical Immature Particles to Barrel-Shaped Infectious Virions (2013) (11)
- Recombinant DNA virus vectors for vaccination. (1990) (11)
- Studies on in vitro expression and in vivo immunogenicity of a recombinant MVA HIV vaccine. (2006) (10)
- Fine structure marker rescue of temperature-sensitive mutations of vaccinia virus within a central conserved region of the genome (1985) (10)
- Characterization of Recombinant Vaccinia Viruses and Their Products (1998) (10)
- The neutralizing antibody response to the vaccinia virus A28 protein is specifically enhanced by its association with the H2 protein. (2010) (10)
- Molecular cloning of the terminal hairpin of vaccinia virus DNA as an imperfect palindrome in an Escherichia coli plasmid. (1985) (9)
- Vaccinia Virus Ankyrin-Repeat/F-Box Protein Targets Interferon-Induced IFITs for Proteasomal Degradation (2019) (9)
- Short Communication: Studies in Macaques on Cross-Clade T Cell Responses Elicited by a DNA/MVA AIDS Vaccine, Better Conservation of CD8 Than CD4 T Cell Responses (2005) (9)
- Multiple Genetic Differences between the Monkeypox and Variola Viruses (2002) (9)
- Production of pro‐opiomelanocortin (POMC) by a vaccinia virus transient expression system and in vitro processing of the expressed prohormone by POMC‐converting enzyme (1989) (9)
- Histidine codons appended to the gene encoding the RPO22 subunit of vaccinia virus RNA polymerase facilitate the isolation and purification of functional enzyme and associated proteins from virus-infected cells. (1999) (9)
- Effect of methylation of the N6 position of the penultimate adenosine of capped mRNA on ribosome binding. (1978) (9)
- Molluscum Contagiosum Virus Transcriptome in Abortively Infected Cultured Cells and a Human Skin Lesion (2016) (9)
- Prospects for prophylactic and therapeutic hepatitis C virus vaccines. (1995) (9)
- Gene Expression Using the Vaccinia Virus/T7 RNA Polymerase Hybrid System (1998) (9)
- Origin of the poxviral membrane: A 50-year-old riddle (2018) (9)
- Synthetic peptides from P. falciparum sexual stage 25-kDa protein induce antibodies that react with the native protein: the role of IL-2 and conformational structure on immunogenicity of Pfs25. (1995) (8)
- DNA Vaccine–Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara Vaccination (2018) (8)
- Role of the vaccinia virus O3 protein in cell entry can be fulfilled by its Sequence flexible transmembrane domain. (2013) (8)
- Immunization with multiple vaccine modalities induce strong HIV-specific cellular and humoral immune responses. (2012) (8)
- Vaccinia growth factor: newest member of the family of growth modulators which utilize the membrane receptor for EGF. (1987) (8)
- Novel Modified Vaccinia Virus Ankara Vector Expressing Anti-apoptotic Gene B13R Delays Apoptosis and Enhances Humoral Responses (2018) (8)
- RNA Polymerase Mutations Selected during Experimental Evolution Enhance Replication of a Hybrid Vaccinia Virus with an Intermediate Transcription Factor Subunit Replaced by the Myxoma Virus Ortholog (2018) (7)
- Colinearity of RNAs with the vaccinia virus genome: anomalies with two complementary early and late RNAs result from a small deletion or rearrangement within the inverted terminal repetition (1982) (7)
- Identification ofFactors Specific forTranscription oftheLateClass ofVaccinia Virus Genes (1989) (7)
- Dinucleotide Sequences at the 5′ Ends of Vaccinia Virus mRNA's Synthesized In Vitro (1980) (7)
- Use of recombinant vaccinia viruses to examine cytotoxic T lymphocyte recognition of individual viral proteins. (1988) (7)
- MVA Vector Vaccines Inhibit SARS CoV-2 Replication in Upper and Lower Respiratory Tracts of Transgenic Mice and Prevent Lethal Disease (2021) (7)
- Synthesis of Vaccinia Viral Proteins in Cytoplasmic Extracts (1969) (7)
- Uses of vaccinia virus as a vector for the production of live recombinant vaccines (1984) (7)
- Transcriptional and Translational Mapping and Nucleotide Sequence Analysis of a Vaccinia Virus Gene Encoding the Precursor of the Major Core Polypeptide 4 b (2003) (7)
- CD 40 L-Adjuvanted DNA / Modified Vaccinia Virus Ankara Simian Immunodeficiency Virus SIV 239 Vaccine Enhances SIV-Specific Humoral and Cellular Immunity and Improves Protection against a Heterologous SIVE 660 Mucosal Challenge (7)
- Expression of the highly conserved vaccinia virus E6 protein is required for virion morphogenesis. (2009) (7)
- Multiple roles for ATP in the synthesis and processing of mRNA by vaccinia virus: specific inhibitory effects of adenosine (beta,gamma-imido) triphosphate. (1978) (7)
- Poxvirus transcriptome analysis (2008) (7)
- Vaccination with Combination DNA and Virus-Like Particles Enhances Humoral and Cellular Immune Responses upon Boost with Recombinant Modified Vaccinia Virus Ankara Expressing Human Immunodeficiency Virus Envelope Proteins (2017) (7)
- Virulence differences of mpox (monkeypox) virus clades I, IIa, and IIb.1 in a small animal model. (2023) (6)
- Rifamycins: Modulation of Specific Anti-Poxviral Activity by Small Substitutions on the Piperazinyliminomethyl Side Chain (1972) (6)
- Specific Anchoring and Local Translation of Poxviral ATI mRNA at Cytoplasmic Inclusion Bodies (2019) (6)
- Vaccinia virus vectors for study of membrane fusion mediated by human immunodeficiency virus envelope glycoprotein and CD4. (1993) (6)
- Rectal Acquisition of Simian Immunodeficiency Virus (SIV) SIVmac239 Infection despite Vaccine-Induced Immune Responses against the Entire SIV Proteome (2020) (6)
- Generation of Recombinant Vaccinia Viruses (2017) (6)
- Inhibition of vaccinia virus replication by N-(phosphonoacetyl)-L-aspartate: differential effects on viral gene expression result from a reduced pyrimidine nucleotide pool. (1997) (6)
- P14-14 LB. A low dose of multigene, multiclade HIV DNA given intradermally induces strong and broad immune responses after boosting with heterologous HIV MVA (2009) (6)
- Characterization of a large, proteolytically processed cowpox virus membrane glycoprotein conserved in most chordopoxviruses. (2015) (6)
- Synthesis of Vaccinia Viral Proteins in Cytoplasmic Extracts (1969) (5)
- Sequence Complexity andRelative Abundance ofVaccinia Virus mRNA'sSynthesized InVivoandInVitro (1978) (5)
- Proliferative T‐Cell Response to HIV Envelope Glycoprotein in Immunized and Infected Primates and Human Beings (1989) (5)
- A homolog of the variola virus B22 membrane protein contributes to ectromelia virus pathogenicity in the mouse footpad model. (2017) (5)
- Decoding poxvirus genome (2015) (5)
- Kinetics and intracellular location of intramolecular disulfide bond formation mediated by the cytoplasmic redox system encoded by vaccinia virus. (2010) (5)
- Generation of recombinant vaccinia viruses. (2001) (4)
- Anti‐HIV Effects of CD4‐Pseudomonas Exotoxin on Human Lymphocyte and Monocyte/Macrophage Cell Lines (1990) (4)
- Studies in macaques on cross-clade T cell responses elicited by a DNA/MVA AIDS vaccine, better conservation of CD8 than CD4 T cell responses. (2005) (4)
- Expression, purification, and characterization of vaccinia virus-encoded RNA and poly(A) polymerases. (1996) (4)
- Vaccinia Virus F 9 Virion Membrane Protein Is Required for Entry but Not Virus Assembly , in Contrast to the Related L 1 Protein (2006) (4)
- Deletion of the Vaccinia Virus I2 Protein Interrupts Virion Morphogenesis, Leading to Retention of the Scaffold Protein and Mislocalization of Membrane-Associated Entry Proteins (2017) (3)
- Erratum for Gjessing et al., Salmon Gill Poxvirus, the Deepest Representative of the Chordopoxvirinae (2015) (3)
- Activity of the 17-Kilodalton Protein Encoded by the Vaccinia Virus AlL Gene (3)
- The Vaccinia Virus A 33 R Protein Provides a Chaperone Function for Viral Membrane Localization and Tyrosine Phosphorylation of the A 36 R Protein (2000) (3)
- Vaccinia virus A43R gene encodes an orthopoxvirus-specific late non-virion type-1 membrane protein that is dispensable for replication but enhances intradermal lesion formation. (2010) (3)
- Spontaneous and Targeted Mutations in the Decapping Enzyme Enhance Replication of Modified Vaccinia Virus Ankara (MVA) in Monkey Cells (2021) (3)
- HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV (2017) (3)
- OA04-03. Characterization of cell-mediated immune responses generated by recombinant modified vaccinia Ankara (rMVA)-HIV-1 in a phase I vaccine trial (2009) (3)
- Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD 4-Pseudomonas exotoxin and reverse transcriptase inhibitors ( AIDS / therapeutics / targeted cell killing / virus replication inhibition ) (3)
- Loss of the Vaccinia Virus 35-Amino-Acid Hydrophobic O3 Protein Is Partially Compensated by Mutations in the Transmembrane Domains of Other Entry Proteins (2021) (2)
- Insights into the Organization of the Poxvirus Multicomponent Entry-Fusion Complex from Proximity Analyses in Living Infected Cells (2021) (2)
- Limits of Specimen Thickness for Energy-Filtered Tomography of Stained Plastic Sections at 120 kV Beam Voltage (2002) (2)
- CHAPTER 15 – Vaccinia Virus Vectors (1992) (2)
- THE CHEMISTRY OF ANTIGENIC VARIATION IN INFLUENZA A VIRUS HEMAGGLUTININ (1978) (2)
- Investigating Viruses during the Transformation of Molecular Biology (2017) (2)
- Therapeutic strategies employing CD4, the HIV receptor. (1992) (2)
- A monkeypox mRNA-lipid nanoparticle vaccine targeting virus binding, entry, and transmission drives protection against lethal orthopoxviral challenge (2022) (2)
- Attenuated Salmonella and Shigella as Live Vectors Carrying Either Prokaryotic or Eukaryotic Expression Systems (2004) (2)
- Genetic Engineering of Vaccinia Virus Vectors: Development of Live Recombinant Vaccines (1986) (2)
- Vaccinia Virus and Other Poxviruses as Live Vectors (2009) (1)
- RemovalofCryptic Poxvirus Transcription Termination Signals fromtheHumanImmunodeficiency VirusType1Envelope GeneEnhances Expression andImmunogenicity of a Recombinant Vaccinia Virus (1990) (1)
- The 2.1 Å structure of protein F9 and its comparison to L1, two components of the conserved poxvirus entry-fusion complex (2018) (1)
- Potent cellular and humoral immunity against HIV-1 elicited in mice by a DNA-prime/MVA-boost vaccine regimen intended for human use (2006) (1)
- CD40L adjuvant for DNA/MVA vaccine: enhanced protection from acquisition of neutralization sensitive & neutralization resistant mucosal SIV infections (2012) (1)
- Recombinant Vaccinia Virus Vaccines (1999) (1)
- HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge (2019) (1)
- Exaptation of inactivated host enzymes for structural roles in orthopoxviruses and novel protein folds revealed by protein structure modeling (2022) (1)
- Expression of Hepatitis B Virus Surface Antigens Containing Pre-s Regions by Recombinant Vaccinia Viruses (1988) (1)
- Virulence Differences of Monkeypox Virus Clades 1, 2a and 2b.1 in a Small Animal Model (2022) (1)
- Folding, Interaction withGRP78-BiP, Assembly, andTransport of theHumanImmunodeficiency VirusType1 Envelope Protein (1991) (1)
- Purification and Characterization of a HeLa Cell Transfer RNA(Cytosine15-)-Methyltransferase* (2001) (0)
- Genome sequence of the molluscum contagiosum virus (1997) (0)
- The use of peptides as therapeutics & vaccines. (1991) (0)
- Enhanced Protection from SARS-CoV-2 Variants by MVA-Based Vaccines Expressing Matched or Mismatched S Proteins Administered Intranasally to hACE2 Mice (2022) (0)
- Proteine synthetique anticomplement, et gene de codage d'une telle proteine (1989) (0)
- Interferon α/β Decoy Receptor Encoded by a Variant in the Dryvax Smallpox Vaccine Contributes to Virulence and Correlates with Severe Vaccine Side Effects (2022) (0)
- Large-scale production, purification and immunological analysis of vaccinia recombinant derived HIV-1 gp160 (1989) (0)
- Expression of HBV envelope and nucleocapsid proteins in human cells using vaccinia virus vectors. (1990) (0)
- Recombinant MVA viruses expressing MODIFIED env, gag and pol genes of HIV CLADE A / G, CLADE CLADE B AND C (2005) (0)
- Protection from SARS-CoV-2 Variants by MVAs expressing matched or mismatched S administered intranasally to mice (2023) (0)
- Characterization andTemporal Regulation ofmRNAs Encoded byVaccinia VirusIntermediate-Sta ge Genes (1993) (0)
- and Efficacy of a DNA/MVA Vaccine but Does Not Diminish Humoral Immunity Decreases SIV-Specific Cellular Immunity Preexisting Vaccinia Virus Immunity (2010) (0)
- a colloquium entitkd " Genetic Engineering of Viruses and of Virus Vectors , " organized by Bernard Roizman and (2005) (0)
- OA07-03. Influence of preexisting vaccinia immunity on a DNA/MVA SIV vaccine, decreased cellular immunity but enhanced control of a pathogenic SIV challenge (2009) (0)
- Two nucleid acid-dependent nucleoside triphosphate phosphohydrolases from vaccinia virus. Purification and characterization. (1974) (0)
- mRNA (NUCLEOSIDE-2′-)METHYLTRANSFERASES FROM HELA CELLS (1980) (0)
- Cytotoxic t cell recognition of influenza virus gene products (1985) (0)
- TheGlycoprotein Products ofVaricella-Zoster VirusGene14and TheirDefective Accumulation ina Vaccine Strain (Oka) (1990) (0)
- P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting (2009) (0)
- Speci fi city and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modi fi ed Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles (2014) (0)
- Polarized expression of viral glycoproteins in epithelial cells infected with recombinant vaccinia virus vectors (1985) (0)
- GM-CSF co-expressing DNA/MVA vaccine, prevention of acquisition by two series of SIVE660 challenges followed by a series of SIV251 challenges (2012) (0)
- Intergenic sites conserved between genes into the genome of Modified Vaccinia Ankara (MVA) -vacciniavirus (2007) (0)
- Inducer-dependent conditional-lethal mutant animal viruses ( lac operator / lac repressor protein / vaccinia virus ) (2004) (0)
- This information is current as Vaccinia Virus Ankara Boost Regimen Vaccinated with a DNA Prime/Modified Blood Lymphocytes from Rhesus Macaques Activity in Fresh, Unstimulated Peripheral Induction of AIDS Virus-Specific CTL (2013) (0)
- Exaptation of Inactivated Host Enzymes for Structural Roles in Orthopoxviruses and Novel Folds of Virus Proteins Revealed by Protein Structure Modeling (2023) (0)
- Human FAM111A inhibits vaccinia virus replication by degrading viral DNA-binding protein I3 and is antagonized by poxvirus host range factor SPI-1 (2023) (0)
- Protein Kinase Activity fromVaccinia Virions: Solubilization andSeparation intoHeat-Labile andHeat-Stable Components (1973) (0)
- Analysis of Viral Membranes Formed in Cells Infected by a 1 Vaccinia Virus L 2-Deletion Mutant Suggest their Origin from 2 the Endoplasmic Reticulum 3 4 (2012) (0)
- GM-CSF co-expressing DNA/MVA vaccine, prevention of acquisition by two series of SIVE660 challenges followed by a series of SIV251 challenges (2012) (0)
- 65. Systemic Cancer Therapy with an Enhanced Tumor-Selective Vaccinia Virus Lacking Anti-Apoptosis Viral Genes Spi-2 and Spi-1 (2004) (0)
- CD40L adjuvant for DNA/MVA vaccine: enhanced protection from acquisition of neutralization sensitive & neutralization resistant mucosal SIV infections (2012) (0)
- Cytoplasmic expression system based on constitutive synthesis of bacteriophage T 7 RNA polymerase in mammalian cells ( cap-independent translation / encephalomyocarditis virus untranslated leader / vaccinia virus ) (0)
- Poxvirus Vectors: Mammalian Cytoplasmic-Based Expression Systems (1991) (0)
- The existence in HeLa cell extracts of two separate (2001) (0)
- 7-Kilodalton Subunit of Vaccinia Virus DNA- Dependent RNA Polymerase with Structural Similarities (0)
- PURIFICATION OF mRNA GUANYLYL TRANSFERASE FROM HELA CELLS (1979) (0)
- A Transcription Factor forExpression ofVaccinia VirusLateGenes IsEncodedbyan Intermediate Gene (1991) (0)
- Mechanisms of Entry of Vaccinia Virus into Cells Studied by Photosensitized Labeling (2011) (0)
- A2L intermediate-stage gene. template: requirement for the product of the Transcription of a vaccinia virus late promoter (2013) (0)
- 18 – CD4-PE40—A Chimeric Toxin Active against Human Immunodeficiency Virus (HIV)-Infected Cells (1991) (0)
- Ansamycins: (A) Rifamycin SV Derivatives (2018) (0)
- vaccinia virus with the cell membrane. Fusion of intra- and extracellular forms of (2013) (0)
- Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters ( hybrid vaccinia virus / chimeric gene / live virus vaccine / recombinant DNA ) (0)
- Multiprotein DNA / MVA Vaccine Control of a Mucosal Challenge and Prevention of AIDS by a (2011) (0)
- Immunodeficiency Virus Variants of Simian-Human Characterization of Primary Isolate-Like (1999) (0)
- Cascade Regulation of Vaccinia Virus Gene Expression (1993) (0)
- Vaccinia Virus RNA Polymerase Gene with Structural Similarity (0)
- Investigating Viruses During the Transformation of Molecular Biology: Part II. (2020) (0)
- Factor-dependent Transcription Termination by Vaccinia Virus (2001) (0)
- Host-Range Determinants of Poxviruses: Anticipating the Next Smallpox (2016) (0)
- Table of Contents (1986) (0)
- VSV/MVA vaccine rapidly elicits SIV antibodies and local and systemic SIV T cell responses in macaque neonates but does not prevent SIV dissemination after oral challenge (2008) (0)
- Characterization of a Newly Identified 35-Amino-Acid Component of the Vaccinia Virus Entry/Fusion Complex Conserved in All Chordopoxviruses (cid:1) (2009) (0)
- Structure of the poxvirus protein F9 (2019) (0)
- Structure of Fab 7D11 from a neutralizing antibody against the poxvirus L1 protein (2007) (0)
- Characterization ofa 7-Kilodalton Subunit ofVaccinia VirusDNA- Dependent RNA Polymerase withStructural Similarities tothe Smallest Subunit ofEukaryotic RNA Polymerase II (1992) (0)
- Receptor S1PR2 and Releasing Antimicrobial Vaccinia Virus by Triggering Mast Cell Skin Mast Cells Protect Mice against (2017) (0)
- A process for the preparation of poxvirus recombinant for the expression of foreign genes. (1983) (0)
- Mva expressing envelope genes, gag and pol HIV modified. (2002) (0)
- Elsevier has created a Monkeypox Information Center in response to the declared public health emergency of international concern, with free information in English on the monkeypox virus. The Monkeypox Information (2012) (0)
- P19-52 LB. Assessing and restructuring foreign gene insertion sites for enhanced stability of modified Vaccinia virus ankara recombinants expressing HIV genes (2009) (0)
- Research with variola virus after smallpox eradication: Development of a mouse model for variola virus infection (2021) (0)
- 5'-Terminal andInternal Methylated Nucleosides inHerpes Simplex VirusType1mRNA (1977) (0)
- Research with variola virus after smallpox eradication: Development of a mouse model for variola virus infection. (2021) (0)
- 140 Induction of Efficacious Immune Responses Using Heterologous Prime: Boost Regimens of Recombinant DNA and MVA Vectored HIV Vaccines and GM-CSF as the Adjuvant (2011) (0)
- 124 GeoVax HIV/AIDS Vaccine Program, Preclinical and Clinical Studies (2012) (0)
- Poxvirus Entry into Host Cells (2010) (0)
- Acid-dependent Nucleoside Triphosphate Phosphohydrolases from Vaccinia Virus NUCLEOTIDE SUBSTRATE AND POLYNUCLEOTIDE COFACTOR (2002) (0)
- Crystal Structure of Vaccinia Virus L1 protein (2005) (0)
- Mutations Near the N Terminus of Vaccinia Virus G9 Protein Overcome Restrictions on Cell Entry and Syncytium Formation Imposed by the A56/K2 Fusion Regulatory Complex (2020) (0)
- Heart Channels in + Heterologously Expressed Serotonin 1 A Receptors Couple to Muscarinic (0)
- Immunity to virus infection (excluding retroviruses) (PP-025) (2010) (0)
- Eukaryotic mRNA capping enzyme-guanylate covalent intermediate ( mRNA guanylyltransferase / HeLa cell / phosphoamide / covalent catalysis ) (0)
- Sedimentation of an RNA polymerase complex from vaccinia virus that specifically initiates and terminates transcription (1987) (0)
- CD4-Pseudomonas Exotoxin: A Strategy for AIDS Therapy Based on Selective Killing of HIV-Infected Cells (1991) (0)
- Faculty Opinions recommendation of The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. (2003) (0)
- Erratum for Sivan et al., “Identification of Restriction Factors by Human Genome-Wide RNA Interference Screening of Viral Host Range Mutants Exemplified by Discovery of SAMD9 and WDR6 as Inhibitors of the Vaccinia Virus K1L−C7L− Mutant” (2017) (0)
- Early promoter-binding factor from vaccinia virions ( transcription factor / DNA-protein complex / poxvirus ) (0)
- Vaccinia Virus Vectors: Applications to Vaccines (1989) (0)
- A recombinant plasmid, method for producing a recombinant avipox virus, recombinant avipox virus, and its use (1988) (0)
This paper list is powered by the following services:
Other Resources About Bernard Moss
What Schools Are Affiliated With Bernard Moss?
Bernard Moss is affiliated with the following schools:
- Stanford University
- Massachusetts Institute of Technology
- Johns Hopkins University
- University of Washington
- Temple University
- University of Massachusetts
- Harvard University
- University of Maryland, College Park
- George Washington University
- University of Alabama
- University of California, Berkeley
- California Institute of Technology
- Massachusetts General Hospital
- New York University
- University of Parma
